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A B S T R A C T
Background
Depression is an important consequence of stroke that impacts on recovery yet is often not detected or inadequately treated. This is an
update of a Cochrane review first published in 2004.
Objectives
To determine whether pharmaceutical, psychological, or electroconvulsive treatment (ECT) of depression in patients with stroke can
improve outcome.
Search methods
We searched the trials registers of the Cochrane Stroke Group (last searched October 2007) and the Cochrane Depression Anxiety
and Neurosis Group (last searched February 2008). In addition, we searched the Cochrane Central Register of Controlled Trials (The
Cochrane Library, Issue 1, 2008), MEDLINE (1966 to May 2006), EMBASE (1980 to May 2006), CINAHL (1982 to May 2006),
PsycINFO (1967 to May 2006) and other databases. We also searched reference lists, clinical trials registers, conference proceedings
and dissertation abstracts, and contacted authors, researchers and pharmaceutical companies.
Selection criteria
Randomised controlled trials comparing pharmaceutical agents with placebo, or various forms of psychotherapy or ECT with standard
care (or attention control), in patients with stroke, with the intention of treating depression.
Data collection and analysis
Two review authors selected trials for inclusion and assessed methodological quality; three review authors extracted, cross-checked and
entered data. Primary analyses were the prevalence of diagnosable depressive disorder at the end of treatment. Secondary outcomes
included depression scores on standard scales, physical function, death, recurrent stroke and adverse effects.
Main results
Sixteen trials (17 interventions), with 1655 participants, were included in the review. Data were available for 13 pharmaceutical agents,
and four trials of psychotherapy. There were no trials of ECT. The analyses were complicated by the lack of standardised diagnostic
and outcome criteria, and differing analytic methods. There was some evidence of benefit of pharmacotherapy in terms of a complete
remission of depression and a reduction (improvement) in scores on depression rating scales, but there was also evidence of an associated
increase in adverse events. There was no evidence of benefit of psychotherapy.
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Authors’ conclusions
A small but significant effect of pharmacotherapy (not psychotherapy) on treating depression and reducing depressive symptoms was
found, as was a significant increase in adverse events. More research is required before recommendations can be made about the routine
use of such treatments.
P L A I N L A N G U A G E S U M M A R Y
Interventions for treating depression after stroke
Antidepressant drugs may be useful in treating depression after stroke, but also cause side effects. Depression is common after stroke and
may be treated with antidepressant medication or psychological therapy. This review of 16 trials, including 1655 participants, found
that antidepressant drugs may produce recovery or improve depression symptoms. However they also increase side effects. These drugs
should be used with caution in people with persistent depressive symptoms after stroke, as little is known about the risks, especially of
seizures, falls, and delirium. We found no evidence for the benefit of psychotherapy. Future research should include a broader group of
stroke patients.
B A C K G R O U N D
Depressive and anxiety disorders are important sequelae of stroke.
These mood disorders occur in at least one third of patients in the
first year after onset of stroke, although estimates differ between
trials due to varying definitions, populations, exclusion criteria,
and the timing of assessments (Hackett 2005a). Inconsistent re-
search findings are also due to the complexity of recognition, as-
sessment and diagnosis of an underlying mood disorder associated
with acute stroke, due to cognitive, language and other impair-
ments. In addition, patients with stroke may experience a variety
of behavioural syndromes that are more specific to brain injury,
including indifference reaction, emotional lability, disinhibition,
unawareness of illness (anosognosia) and difficulties with emo-
tional expression (aprosody). In particular, much of the contro-
versy surrounding ’stroke-associated depression’ as a specific type
of depressive syndrome hinges on concern about whether the tools
normally used for the diagnosis of major depression and other
depressive illnesses may misattribute features of ischaemic brain
injury to depression (House 1987; Johnson 1991). Moreover, re-
sults will depend on whether subjects are categorised on the basis
of psychiatric interview using standard diagnostic criteria such as
the Diagnostic and Statistical Manual of Mental Disorders (e.g.
DSM-IIIR, DSM-IV) (APA 1987; APA 1994) or psychiatric rat-
ing scales such as theMontgomery ÅsbergDepressionRating Scale
(MADRS) (Montgomery 1979), or based on self assessment using
a rating scale of mood.
Although there is continued controversy about whether this ill-
ness is predominantly caused by physical factors (such as stroke
lesion location) or by the patients’ psychological response to stroke
(Carson 2000), evidence suggests that clinically diagnosed stroke-
associated depression has a similar frequency and nature to de-
pression among older people with other chronic illnesses (Burvill
1996; Burvill 1997; Sharpe1990).While it was previously thought
that the period of greatest risk appeared to be within the first few
months of stroke onset (Burvill 1995a; Herrmann 1998; House
1991) this was not apparent in a systematic review of high-quality
observational studies (Hackett 2005a). While some patients re-
cover spontaneously, up to one third of patients have depression
that persists during the first year or longer after the onset of stroke
(Astrom 1996; Herrmann 1998). Patients with ’anxious depres-
sion’ and those with more severe symptoms at presentation appear
less responsive to treatment and have a worse long-term prognosis
(Astrom 1996).
Evidence of a causal relationship between stroke-associated depres-
sion and adverse outcomes is complicated by potential confound-
ing factors such as age, gender, social class, physical disability and
co-morbid conditions. However, the evidence suggests that abnor-
mal mood may impede rehabilitation (Parikh 1990; Sinyor 1986)
by impairing physical and cognitive function (Robinson 1986),
and contributing to stress on carers (Anderson 1995a). Further-
more, stroke-associated depression may also be associated with an
increased risk of death (House 2001; Morris 1993b) including
death by suicide (Stenager 1998). Depressive illness among older
people, in general, is associated with greater morbidity and depen-
dency, higher use of drugs and alcohol, increased use of health-
care resources, and poor compliance with treatment of co-morbid
conditions (Katona 1995).
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Although depressionmay influence recovery and outcomes follow-
ing stroke, many, perhaps most, patients do not receive effective
treatment because their mood disorder is undiagnosed or inade-
quately treated. Ebrahim 1987a, for example, found that few pa-
tients with stroke-associated depression had been given antidepres-
sants following discharge from hospital, while House et al (House
1989) reported that both general practitioners and hospital doc-
tors had a passive attitude to therapy. While this invariably re-
flects the problems with the diagnosis of a ’significant’ mood state
among older people with disability, it may also reflect uncertainty
among clinicians as to the balance of benefits and risks (including
side effects) of therapies in this setting. Indirect evidence of the
effectiveness of pharmacological and psychological treatments for
depression (and anxiety) for older people in general, and in those
with associated physical illness, are available in several published
reviews (Gill 2000; Lima 2001;McCusker 1998;Mittmann 1997;
Wilkinson 1997). However, because of the possibility that depres-
sion after stroke differs in important ways, it may be inappropriate
to extrapolate these data to patients with stroke.
We undertook a systematic review of all randomised controlled tri-
als (RCTs) (published and unpublished) of pharmaceutical agents,
psychological therapies or electroconvulsive therapy (ECT) for the
treatment of depression associated with stroke.
This is an update of a Cochrane review first published in 2004.
O B J E C T I V E S
To determine whether treatment of depression in patients with
stroke improves outcome in terms of reduction in the proportion
of patients with diagnosable depressive disorder. Secondary objec-
tives were to determine whether treatment of depression improves
mood scores, physical functioning, and health related quality of
life, and reduces dependency either in patients or principle care-
givers. We also aimed to determine the safety of and adherence to
such treatments.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We restricted the review to all relevant RCTs in patients with a
clinical diagnosis of stroke, where a pharmaceutical agent, psycho-
logical therapy, or ECT, used for the treatment of depression, was
compared with placebo or standard care. We excluded trials using
a cross-over design, or in which two or more of the interventions
were compared with each other rather than with a placebo or stan-
dard care group. There was no restriction on eligibility of RCTs
on the basis of language, sample size, duration of follow up, or
publication status.
Trials that met all the inclusion criteria, but in which no outcome
data were available (either from the report of the trial or from the
authors), could not contribute meaningfully to a pooled estimate
of effect. These trials were regarded as ’drop outs’ rather than inel-
igible, and are listed in an Additional Table (Table 1), to indicate
that they have not been overlooked.
Types of participants
Wedefined stroke according to clinical criteria. These include cere-
bral infarction, intracerebral haemorrhage and ’uncertain’ patho-
logical subtypes. This review excludes trials of patients with sub-
arachnoid haemorrhage (SAH) only, as this entity has a different
natural history and management strategy from other stroke sub-
types. However, we did include trials with mixed stroke subtypes,
including small numbers of SAH patients. There were no restric-
tions on the basis of age, sex or other characteristic. Participants
were required to have depression (diagnosed by psychiatric inter-
view, mood scale, or treating clinician) on recruitment. We ex-
cluded trials with participants who were not depressed at recruit-
ment, but that measured depression as the primary outcome at
follow up. These trials were included in a review of interventions
for preventing depression after stroke (Hackett 2008).
The diagnostic categories of depression considered were:
(1) depressive disorder, as defined by symptom scores on a standard
screening instrument;
(2) major depression, as defined by the American Psychiatric As-
sociation Diagnostic and Statistical Manual of Mental Disorders
(DSM-IIIR, DSM-IV; APA 1987; APA 1994) or similar diagnos-
tic criteria;
(3) dysthymia or minor depression, as defined by DSM or other
standard diagnostic criteria.
Trials that included mixed populations (such as stroke and head
injury or other central nervous system disorders) were excluded
unless separate results for the stroke patients could be identified.
Patients were excluded if they were being treated primarily for a
stroke-associated pain syndrome, even if depression was measured
as a secondary outcome.
Types of interventions
We included any trial that attempted to evaluate the following.
(1)A comparisonbetween a pharmacological agent andplacebo for
the treatment of depression associated with stroke. Specific phar-
macological agents included tricyclic antidepressants (for exam-
ple nortriptyline, imipramine, and clomipramine), selective sero-
tonin reuptake inhibitors (SSRIs) (for example fluvoxamine, flu-
oxetine, sertraline, citalopram and paroxetine), monoamine oxi-
dase inhibitors (MAOIs) (for example moclobemide), and other
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antidepressant medications. Trials of an agent that was being
evaluated for other reasons (for example neuroprotection or to
facilitate neuro-regeneration) with a mood endpoint were ex-
cluded. We found no trials of psychostimulants (for example
methylphenidate), mood stabilisers (for example lithium) or ben-
zodiazepines. We found one trial of a combined preparation
(Deanxit) which was included but analysed separately.
(2) A comparison between ECT and standard care for the treat-
ment of depression associated with stroke. We found no trials of
ECT. Any future trials will be included but analysed separately.
(3) A comparison between a psychological therapy and standard
care for the treatment of depression associated with stroke. We
included any psychological therapy that involved direct patient-
professional interaction. The content of the interaction could vary
fromcounselling to specific psychotherapy provided itwas directed
at helping patients develop their social problem-solving skills and
adjustment to the emotional impact of stroke. All interventions
had to have a psychological component - talking, listening, sup-
port, advice; be based on a theory of talking therapy; be structured
and timetabled as a talking therapy; and be delivered by somebody
with some explicitly stated training and supervision in therapies.
Exclusions included interventions whose sole purpose was to ed-
ucate or to provide information, occupational therapy (including
leisure therapy and other rehabilitation services), and visits from
stroke support workers, unless there was a clearly defined psycho-
logical component.
Types of outcome measures
The primary analyses focused on the proportion of patients who
could no longer be diagnosed according to diagnostic categories
of depression that were applied by the trial authors at the end of
the follow-up period (remission). These included:
(1) no longer meeting the criteria for depression or dysthymia as
defined by DSM or similar standard diagnostic criteria;
(2) scoring below cut points for depressive disorder, as defined by
symptom scores on standard rating scales.
Secondary outcomes were as follows.
(1) Depression, as measured on scales such as the Hamilton De-
pression Rating Scale (HDRS, Hamilton 1960), Montgomery
Åsberg Depression Rating Scale (MADRS, Montgomery 1979),
Geriatric Depression Scale (GDS, Gompertz 1993), Beck Depres-
sion Inventory (BDI, Beck 1961), and Hospital Anxiety and De-
pression Scale (HADS Depression sub-scale, Zigmond 1983).
(2) Psychological distress, as measured on composite scales such
as the General Health Questionnaire (GHQ, Goldberg 1972).
(3) Anxiety, as measured on scales such as the Hamilton Anxiety
Scale, Beck Anxiety Inventory, and the Hospital Anxiety and De-
pression Scale (HADS Anxiety sub-scale, Zigmond 1983).
(4) Cognition, as measured on scales such as the Mini-Mental
State Examination (MMSE, Folstein 1975).
(5) Activities of daily living, as measured on scales such as the
Barthel Index (BI, Mahoney 1965).
(6) Disability, as measured on scales such as the Functional Inde-
pendence Measure (FIM, Deutsch 1997).
(7) Disadvantages of treatment were recorded as adverse events,
grouped by death, all, and leaving the study early (including
death).
Participants’ reason for withdrawal from the trials was examined
as a marker of acceptance.
We have identified the following additional endpoints for use in
subsequent reviews, if measured.
• General health, as measured on composite scales such as the
Nottingham Health Profile (NHP, Hunt 1986).
• Social activities, as measured on scales such as the Frenchay
Activities Index (FAI, Wade 1985).
• HRQoL, as measured on scales such as the 36-item short
form questionnaire (SF-36, Ware 1993).
• Proportion reporting dependence in self-care ADL on the
modified Rankin Scale (mRS, Rankin 1957).
• Principal caregiver HRQoL and stress.
Search methods for identification of studies
See: ’Specialized register’ section in Cochrane Stroke Group
We searched the trials registers of the Cochrane Stroke Group (last
searched by the Review Group Co-ordinator in October 2007)
and the Cochrane Depression Anxiety and Neurosis Group (last
searched February 2008). In addition, we searched the Cochrane
Central Register of Controlled Trials (The Cochrane Library, Is-
sue 1, 2008), MEDLINE (1966 to May 2006) (Appendix 1),
EMBASE (1980 to May 2006), CINAHL (1982 to May 2006),
PsycINFO (1967 toMay 2006), Applied Science and Technology
Plus (1986 to May 2006), Arts and Humanities Index (1991 to
September 2002), Biological Abstracts (1969 to September 2002),
BIOSISPreviews (2002 toMay 2006),General Science Plus (1994
to September 2002), Science Citation Index (1992 toMay 2006),
Social Sciences Citation Index (1991 to May 2006), SocioFile
(1974 to May 2006) and ISI Web of Science (2002 to February
2008). Biological Abstracts has now been superseded by BIOSIS
Previews and ISI Web of knowledge includes the Arts and Hu-
manities Index. We have not updated the searches on General Sci-
ence Plus as this electronic database is not available for the current
authors.
(1) We searched Dissertations and Theses (previously called Digi-
tal Dissertations), a database of abstracts from doctoral theses from
within the United States, Canada, Scandinavia and the United
Kingdom (1980 to August 2007).
(2) We searched the proceedings of the European Stroke Confer-
ences (2000 to 2007) and the Stroke Society of Australasia Annual
Scientific Meetings (1999 to 2007).
(3) In 2002 we contacted by letter several of the researchers active
the area of stroke-associated mood disorders in the previous 10
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years. We identified these researchers by scanning author lists of
the relevant published trials, reviews and conference proceedings.
We asked them to verify that all relevant trials had been identified
and also if they had knowledge of any other relevant published or
unpublished trials. We have not contacted them for this review
update.
(4) In 2002 we contacted major pharmaceutical companies by
letter and asked if they knew of any relevant unpublished trials.
We did not contact them for this update. However, we searched
the online Clinical Trial Results and Clinical Trial Registries for
Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Novar-
tis, Organon, Pfizer, Roche, and Wyeth (to August 2007).
(5) We searched the online clinical trials and research registers
www.strokecenter.org/trials, www.ClinicalTrials.gov,
www.Clinicalstudyresults.org and www.anzctr.org.au (to August
2007). The compulsory registration of clinical trial protocols on
these sites before recruitment of the first patient, enabled us to
elect not to contact researchers and pharmaceutical companies.
(6)We reviewed chapters in books on the prevention and treatment
of depression andmanagement of stroke, including but not limited
to, reviews of themanagement of stroke, books specifically directed
at the treatment or prevention of depression, and those on stroke
and old age.
Data collection and analysis
Two review authors (MH and CH) reviewed all citations and dis-
carded those that were irrelevant, based on the title of the publi-
cation and its abstract. In the presence of any suggestion that an
article was possibly relevant, we retrieved the full-length article for
further assessment. MH and CH independently selected the trials
for inclusion in the review from the culled citation list. Poten-
tially relevant Chinese articles were translated by JX. We resolved
disagreements by discussion, and CA confirmed the final list and
adjudicated any persisting differences of opinion.
Data extraction
MH, CH and JX independently extracted, cross checked and en-
tered the data on forms designed for the purpose. We discussed
and resolved any discrepancies before we entered the data into the
Review Manager software, RevMan 4.2.
We collected data on:
• the report: author, year, and source of publication;
• the study: sample characteristics, social demography,
definition and criteria used for depression;
• the patients: stroke sequence (first ever versus recurrent),
social situation, time elapsed since stroke onset, prior history of
psychiatric illness, current neurological status, current treatment
for depression, and a history of coronary artery disease;
• the research design and features: sampling mechanism,
treatment assignment mechanism, adherence, non-response, and
length of follow up;
• the intervention: type, duration, dose, timing, and mode of
delivery;
• the effect size: sample size, nature of outcome, estimate and
standard error.
To allow for intention-to-treat (ITT) analysis, we sought the data
irrespective of their adherence, and regardless of whether the pa-
tients were subsequently deemed ineligible, or otherwise excluded
from treatment or follow up.
We checked all the extracted data for agreement between review
authors. We obtained missing information from the primary in-
vestigators whenever possible. To avoid introducing bias, this un-
published information was obtained in writing, on forms designed
for the purpose, and entered into RevMan.
Study characteristics
Although there are a number of scales devised for assessing the
quality of RCTs, there is no convincing evidence that complex
and time-consuming scales are more effective than simple scales
(Verhagen 2001). As we extracted data, we documented specific
details about the following five points.
(1) Generation of the randomisation sequence: the method used;
was the study described as randomised, and a genuine randomi-
sation process described; was this adequate, inadequate, or un-
known? If the randomisation was blocked, was the size of the
blocks known to those entering patients. Adequate randomisation
= 1, inadequate/unknown randomisation = 0.
(2) Concealment of the random sequence from those entering pa-
tients into the trial: the method used; was it one that ensured tam-
per-free concealment of allocation; was it adequate, inadequate
or unknown? Concealed randomisation = A, not concealed/un-
known = B, and insecure = C.
(3) Who was blinded and how successful was blinding? Was the
patient, health worker treating the patient, or the follow up raters
blinded, andwere attemptsmade to check blindingwas successful?
(4) How many participants in each treatment group who were
initially randomised were not included in the analysis? Was an
ITT analysis possible on all participants from the published data
(were there any exclusions from the trial after randomisation, or
for cross over treatment groups)?
(5) How many patients were withdrawn from the trial, crossed-
over treatment groups, or were lost to follow up (including when
the proportion of patients who were lost to follow up was less than
20%)?
MH and CA independently assessed the methodological charac-
teristics of each trial using the above checklist. The two review
authors thenmet for a consensus meeting. They resolved disagree-
ments by discussion, and a third review author (AH) resolved any
persisting differences of opinion. For each included trial, we de-
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scribed features that influenced the degree of bias, as well as dif-
ferences in baseline prognostic variables that might invalidate the
results. One or more of these variables could be used to undertake
sensitivity analyses in subsequent reviews.
Statistical analysis
The main outcome of interest was the proportion of participants
who met the diagnostic, or scoring, categories for depression at
the end of follow up. For all dichotomous outcomes, we calcu-
lated odds ratios (OR), with 95% confidence intervals (CI) where
appropriate using fixed-effect analyses.
For continuous outcomes, if ordinal scale data appeared to be ap-
proximately normally distributed or if the analysis suggested para-
metric tests were appropriate, we treated the outcome measures as
continuous variables. If there were at least two trials that reported
the same outcomes, we reviewed the data for appropriateness of
pooling. If there was definite evidence of heterogeneity (I2 > 50%),
we explored the potential reasons for the differences by performing
subgroup or sensitivity analyses. If the heterogeneity could not be
explained, we combined the trials using random-effects analyses
with cautious interpretation, or did not combine them at all.
We used the RevMan software (RevMan 4.2) where possible; we
used Excel and SAS for other analyses.
Subgroup and sensitivity analyses
If there was definite evidence of heterogeneity, we explored poten-
tial reasons for the differences by performing subgroup analyses,
sensitivity analyses, and meta-regression (Normand 1999).Where
possible, we had planned to perform subgroup analyses to examine
the impact of treatment type and duration, and of stroke severity.
We were to undertake sensitivity analyses to explore the influence
of date of publication, sample size, method of diagnosing depres-
sion, duration of follow up, high (greater than 20%) number of
drop outs, and blinded versus unblinded outcome assessors. The
sensitivity of the combined estimate to individual trials was to be
explored by leaving one study out, calculating the combined effect
of the remaining trials, and comparing the results with the com-
bined effect based on all the trials. If meta-analyses are undertaken
in updates of this review, funnel plots will be used to detect the
presence of publication bias and the Trim and fill technique will be
used to determine whether our results are sensitive to publication
bias (Duval 2000).
These were not completed for the current version of this review.
Additional requested data
We wrote to the authors of all newly included, ongoing and drop-
out studies requesting data that were unavailable, or ambiguous in
the published articles. We received responses with additional data
from authors of two new trials (Lai 2006a;Watkins 2007). In 2004
we received responses with regard to six trials (Andersen 1994;
Downes 1995; Fruehwald 2003; Lincoln 2003; Murray 2002;
Reding 1986, Towle 1989). We received no response from the
remaining authors. We also wrote to all pharmaceutical companies
known to produce, or have a licence to produce, antidepressants
in 2004. We received nine replies identifying no new trials.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Seven new trials (Jiang 2001a; Lai 2006a; Ponzio 2001; Rampello
2005; Watkins 2007; Yang 2002; Zhao 2004) have been included
since the previous published version of this review resulting in 16
included trials (17 interventions), with 1655 participants at entry,
for inclusion (Andersen 1994; Fruehwald 2003; Jiang 2001a;
Jiang 2001b; Lai 2006a; Lincoln 2003; Lipsey 1984; Murray
2002;Ohtomo1991; Ponzio 2001; Rampello 2005; Reding 1986;
Towle 1989; Watkins 2007; Wiart 2000; Yang 2002; Zhao 2004).
Another eight trials require more information before we decide
on inclusion or not. Lincoln 2003 compared an active treatment
with an attention-control (the time spent by participants in the
treatment group with a trained therapist was controlled in the
attention-control group by participants spending an equal amount
of time in focused conversation), as well as a control (standard care)
group. We combined data from the attention-control and control
group, and compared this with data for the treatment group. Jiang
2001a compared two active treatment arms with a placebo arm.
We compared data from both treatment arms (Jiang 2001a; Jiang
2001b) with data from half the number of participants in the
placebo arm and presented the results as two separate trials. More
detailed information is provided in Characteristics of included
studies.
We identified nine additional trials (Choi-Kwon 2006; Downes
1995; Graffagnino 2003; Isenberg 2000; Mauri 1988; Meara
1998; Ohtomo 1985; Xie 2003; Zhou 2004) that met the inclu-
sion criteria for this review. However, no outcome data were avail-
able (unpublished data only, Downes 1995; Graffagnino 2003;
Isenberg 2000; data not presented by treatment group or in a suit-
able format, Choi-Kwon 2006;Mauri 1988;Meara 1998; requires
translation, Ohtomo 1985, or method of assessment of mood un-
clear Xie 2003; Zhou 2004). These trials are considered ’drop outs’
and more detailed information on these trials is provided in Table
1. Another three trials (Graven 2008; Mitchell 2002; Thomas
2007) are currently ongoing.
A total of 167 trials were excluded. In 93 trials there was no placebo
(pharmaceutical trials) nor usual care (psychotherapy trials) com-
parison arms, and in 55 the intervention did not meet the review
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criteria. The remaining trials were excluded for the variety of rea-
sons listed.
Participants
Sociodemography
The mean age of participants ranged from 60 to 78 years. Six
trials had balanced proportional frequencies of males and females (
Lincoln 2003; Lipsey 1984; Ponzio 2001; Rampello 2005; Reding
1986; Watkins 2007); four had more males in the control group
(Andersen 1994; Fruehwald 2003; Jiang 2001a; Jiang 2001b),
and five had more males in the active treatment group (Murray
2002; Towle 1989; Wiart 2000; Yang 2002; Zhao 2004), with the
percentage of males ranging from 30% to 71%. The proportion
of males was unknown in two trials (Lai 2006a; Ohtomo 1991).
Stroke details
Six trials included participants with stroke due to intracerebral
haemorrhage as well as cerebral infarction, five specified the diag-
noses was made on the basis of a combination of standard clinical
and CT criteria (Andersen 1994; Fruehwald 2003; Lipsey 1984;
Rampello 2005; Wiart 2000), with the frequency of CT reported
at 100% (Yang 2002 did not specify themethod of diagnosis). Five
trials included all stroke subtypes (Lincoln 2003; Murray 2002;
Reding 1986; Towle 1989; Watkins 2007) with two reporting a
CT rate of 100% (Murray 2002;Watkins 2007), one trial included
only cases of cerebral infarction (Ohtomo 1991) and five did not
specify stroke details (Jiang 2001a; Jiang 2001b; Lai 2006a; Ponzio
2001; Zhao 2004).
Recruitment time window
The average time from stroke onset to entry into trials ranged
from ’within a few days’ (Fruehwald 2003) to 25 months (Towle
1989). Six trials included patients within one month of stroke
onset (Andersen 1994; Fruehwald 2003; Lipsey 1984; Murray
2002; Watkins 2007; Wiart 2000). The time window from stroke
onset to randomisation was wide (several months to more than
two years) for seven trials (Andersen 1994; Lincoln 2003; Lipsey
1984;Murray 2002; Rampello 2005; Towle 1989; Yang 2002) and
narrow (several days to several weeks) for four trials (Fruehwald
2003; Reding 1986;Watkins 2007;Wiart 2000). One trial (Towle
1989) specifically excluded patients with a stroke onset of less than
one year from randomisation.Details of the timewindow for entry
are uncertain for three trials (Lai 2006a; Ohtomo 1991; Ponzio
2001).
Exclusion criteria
Nine trials employed criteria that excluded patients with vary-
ing degrees of communication and/or cognitive difficulties and/
or other co-existing conditions that would interfere with out-
come assessments or participation in the treatment regimens
(Andersen 1994; Fruehwald 2003; Lipsey 1984; Murray 2002;
Ponzio 2001; Rampello 2005; Watkins 2007; Wiart 2000; Zhao
2004). Other specific reasons for exclusion included: a history of
depression in the last year (Andersen 1994) or previous five years
(Lincoln 2003); on antidepressant medication (Andersen 1994;
Jiang 2001a; Jiang 2001b; Lipsey 1984;Murray 2002) or receiving
psychotherapy (Ponzio 2001; Watkins 2007); concurrent psychi-
atric illness (Murray 2002; Ponzio 2001; Rampello 2005; Wiart
2000); any contraindication to the study treatment (Lipsey 1984;
Ponzio 2001; Wiart 2000) or where there was concurrent use of
antiarrhythmic medication (Reding 1986); a history of myocar-
dial infarction within the previous month (Murray 2002; Reding
1986); a stroke in the year prior to randomisation (Towle 1989);
inability to speak English, blindness or deafness (Lincoln 2003);
living outside the specific locality (Lincoln 2003; Watkins 2007);
living in a hospital or in residential care (Towle 1989); and sub-
stance dependency (Ponzio 2001; Rampello 2005).Details are un-
clear for three trials (Lai 2006a; Ohtomo 1991; Yang 2002).
Setting
Six trials recruited patients from outpatient clinics or from home
after they had been discharged from hospital (Lincoln 2003;
Ponzio 2001; Rampello 2005; Towle 1989; Yang 2002; Zhao
2004); six trials recruited only inpatients soon after stroke onset
(Fruehwald 2003; Jiang 2001a; Jiang 2001b; Lai 2006a; Reding
1986; Watkins 2007); and three trials used mixed inpatient and
outpatient sources of patients (Andersen 1994; Lipsey 1984;
Murray 2002). Details are unclear for two trials (Ohtomo 1991;
Wiart 2000).
Interventions
Twelve trials assessed 13 pharmacological interventions (Andersen
1994; Fruehwald 2003; Jiang 2001a; Jiang 2001b; Lai 2006a;
Lipsey 1984; Murray 2002; Ohtomo 1991; Ponzio 2001;
Rampello 2005; Reding 1986; Wiart 2000; Yang 2002), and four
assessed psychological interventions (Lincoln 2003; Towle 1989;
Watkins 2007; Zhao 2004). Results from these trials are presented
and discussed separately.
Pharmacotherapy
Among the trials of pharmacological treatments, seven trials com-
pared an SSRI (citalopram, Andersen 1994; fluoxetine, Fruehwald
2003;Wiart 2000; paroxetine Lai 2006a; Ponzio 2001; Yang 2002;
sertraline Murray 2002) against placebo; two trials compared a
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tricyclic antidepressant (amitriptyline, Jiang 2001a; nortriptyline,
Lipsey 1984) against placebo; and other treatments with antide-
pressant effects were used in four trials (deanxit Jiang 2001b,
aniracetam Ohtomo 1991, reboxetine Rampello 2005, trazodone
Reding 1986). Five trials used a flexible dose regimen, with a lower
dose in older people and/or dose escalation for persistently ele-
vated mood scores during follow up (Andersen 1994; Fruehwald
2003; Jiang 2001a; Lipsey 1984; Murray 2002; Reding 1986).
Six trials (Jiang 2001b; Lai 2006a; Ohtomo 1991; Ponzio 2001;
Rampello 2005; Wiart 2000; Yang 2002) used a fixed dose. The
duration of treatment was generally short, ranging from four to six
weeks (Andersen 1994; Lipsey 1984; Reding 1986; Wiart 2000)
to 12 weeks (Fruehwald 2003; Lai 2006a; Ohtomo 1991) to 16
weeks (Rampello 2005; Yang 2002). Murray 2002, Jiang 2001a
and Jiang 2001b provided treatment with a target duration of 26
weeks.
Psychotherapy
The forms of psychotherapy included problem-solving therapy
with counselling delivered by social workers (Towle 1989), more
structured cognitive behavioural therapy (CBT) delivered by
nurses (Lincoln 2003), motivational interviewing (MI) delivered
by nurses and non-clinical psychologists (Watkins 2007), and a
supportive psychological intervention including education deliv-
ered by special personnel (Zhao 2004). The frequency and dura-
tion of sessions was individually tailored to the needs of the patient
in three trials, so that the duration of treatment ranged from daily,
less than 30 minute, sessions over four weeks (Zhao 2004), seven
to 10 one-hour sessions over three months (Lincoln 2003), to four
to six months (Towle 1989). In the most recent trial (Watkins
2007) all patients received up to four individual sessions of 30 to
60 minutes over four weeks (one per week). Three trials used stan-
dard care as the control comparison (Towle 1989; Watkins 2007;
Zhao 2004) and the other used both a standard care control and
an attention-control group (Lincoln 2003).
Depression criteria
A wide variety of criteria and methods were used to diagnose
depression in the included trials: eight trials included patients
who had high scores only on standard depression scales such as
the HDRS (Jiang 2001a; Jiang 2001b; Lai 2006a; Yang 2002;
Zhao 2004 with cutpoint scores varying from 6 (Lai 2006a) to
20 (Rampello 2005)), the MADRS (cutpoint of 18 Ponzio 2001)
and either theWDI (cutpoint 17) or GHQ-28 (cutpoint 9, Towle
1989), or the GHQ-28 alone (cutpoint 4, Watkins 2007); two
trials included patients with depressive illness diagnosed by psy-
chiatric interview using standard psychiatric criteria (Lipsey 1984;
Reding 1986); five trials used a combination of psychiatric in-
terview and high scores on a depression scale (Fruehwald 2003,
HDRS cutpoint 15; Lincoln 2003, BDI cutpoint 10, WDI cut-
point 18; Murray 2002, MADRS cutpoint 9; Rampello 2005,
HDRS cutpoint 20, BDI cutpoint 15; Wiart 2000, MADRS cut-
point 19); and one trial used a transformation of symptom do-
main scores from a standard depression scale (HDRS) to derive
a DSM-III-R diagnosis of depression (Andersen 1994). The re-
maining trial included patients based on the ’physician’s impres-
sion’ (Ohtomo 1991).
Outcome measures
Depression
Eight assessment scales were used to assess mood or assess change
inmood at the endof treatment innine trials. Themost commonly
used measure was the HDRS (Andersen 1994; Fruehwald 2003;
Jiang 2001a; Jiang 2001b; Lai 2006a; Lipsey 1984; Rampello
2005; Yang 2002; Zhao 2004). Seven trials used two ormore scales
to assess abnormal mood or depression (Fruehwald 2003; Lincoln
2003; Lipsey 1984; Ponzio 2001; Rampello 2005; Towle 1989;
Watkins 2007), one trial determined depression by psychiatric
interview and a scale (Reding 1986) and one relied on physician
impression (Ohtomo 1991).
Additional outcomes
A wide variety of additional measures were used in the trials (see
Characteristics of included studies). Most trials only presented se-
lected outcome data. Only six trials presented data from all ques-
tionnaires listed as being administered (Jiang 2001a; Jiang 2001b;
Ponzio 2001; Towle 1989; Watkins 2007; Wiart 2000). Adverse
event data were often not reported or reported poorly.
Risk of bias in included studies
Generation and concealment of randomisation
sequence
Six trials used an appropriately generated and clearly concealed
randomisation procedure (Andersen 1994; Fruehwald 2003;
Lincoln 2003; Murray 2002; Towle 1989; Watkins 2007). The
randomisation sequence appeared to be appropriately generated in
nine trials (Andersen 1994; Fruehwald 2003; Lincoln 2003; Lipsey
1984; Murray 2002; Rampello 2005; Reding 1986; Towle 1989;
Watkins 2007), however, not all trials described adequate conceal-
ment of allocation (Jiang 2001a; Jiang 2001b; Lai 2006a; Lipsey
1984;Ohtomo1991; Ponzio 2001; Rampello 2005; Reding 1986;
Wiart 2000; Yang 2002; Zhao 2004).
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Blinding of participants and outcome assessors
Four of the pharmacotherapy trials used an unequivocal double-
blinded outcome assessment for all patients (Fruehwald 2003;
Lipsey 1984;Murray 2002; Reding 1986). Four trials stated a dou-
ble-blind method but did not state who was blinded (Andersen
1994; Ohtomo 1991; Ponzio 2001; Wiart 2000) and in one trial
the outcome assessor was not blinded (Rampello 2005). Three
psychotherapy trials used single (assessor) blinded outcome assess-
ment (Lincoln 2003; Towle 1989; Watkins 2007), details were
unclear for the remaining trials (Jiang 2001a; Jiang 2001b; Lai
2006a; Yang 2002; Zhao 2004).
Method of analysis
Six trials reported per-protocol analyses (Fruehwald 2003; Jiang
2001a; Jiang 2001b; Lincoln 2003; Lipsey 1984; Towle 1989),
four provided ITT analyses (Ponzio 2001; Reding 1986; Watkins
2007; Wiart 2000), and two used ITT in addition to per-protocol
analyses (Andersen 1994; Murray 2002). The method of analysis
was unclear in five trials (Lai 2006a; Ohtomo 1991; Rampello
2005; Yang 2002; Zhao 2004).
Trial size and participants leaving the trial early
The pharmacotherapy trials ranged in size from 17 (Reding 1986)
to 285 (Ohtomo 1991) participants, with the drop-out rate rang-
ing from 0% (Jiang 2001a; Jiang 2001b; Ponzio 2001; Rampello
2005; Reding 1986) to 44% (Murray 2002). In the four psy-
chotherapy trials, the number of participants ranged from 44
(Towle 1989) to 254 (Watkins 2007), with drop-out rates ranging
from 2% (Towle 1989) to 6% (Lincoln 2003).
Effects of interventions
Overall, 1655 participants were included in this review. In view of
the large number and heterogeneous nature of the outcome mea-
sures and the reporting of results, we considered it inappropriate
to pool outcome data for many endpoints.
Pharmacotherapy
Outcome data were available for 12 antidepressant interventions
including 1121 participants (Andersen 1994; Fruehwald 2003;
Jiang 2001a; Lai 2006a; Lipsey 1984; Murray 2002; Ohtomo
1991; Ponzio 2001; Rampello 2005; Reding 1986; Wiart 2000;
Yang 2002). There was evidence of a benefit of pharmacotherapy
in treating depression (remission) with a pooled OR of 0.47 (95%
CI 0.22 to 0.98, Analysis 1.1) in the binary outcome measures
the trial authors used, however there was substantial heterogene-
ity across individual studies. There was also evidence of a benefi-
cial effect of pharmacotherapy in reducing (improving) scores on
mood rating scales (response), however, because of the multiple
scales used to assess mood in several individual trials (Andersen
1994; Fruehwald 2003; Lipsey 1984; Rampello 2005), we did not
perform a meta-analysis (Analysis 1.2 and Analysis 1.3). Benefit of
pharmacotherapy was also seen in the proportion of participants
reporting a 50% or greater reduction in mood scores (OR 0.22,
95% CI 0.09 to 0.52, Analysis 1.4), however, confidence intervals
were wide for this endpoint and for average mood scores at the end
of treatment which included significant effects both in favour of
treatment and in favour of control. There was no evidence of bene-
fit of pharmacotherapy in improving cognitive function. One trial
showed a significant benefit on pharmacotherapy on anxiety (OR
0.48, 95% CI 0.26 to 0.88, Analysis 1.5) (Ohtomo 1991). There
was no evidence of benefit of pharmacotherapy in improving ac-
tivities of daily living, or reducing disability, as demonstrated by
heterogeneous results with wide confidence intervals. Significant
evidence of harm was demonstrated in adverse events (see Analysis
1.14), in particular central nervous systemOR 1.96 (95%CI 1.19
to 3.24), gastrointestinal OR 2.37 (95% CI 1.38 to 4.06) and
other less specific adverse events OR 1.51 (95% CI 0.91 to 2.34).
Outcome data were available for one combination preparation
(Deanxit, a combination of flupentixol and melitracen) that in-
cluded 45 people (Jiang 2001b). There was evidence of a benefit of
pharmacotherapy in improving mood scores (secondary outcome,
mean difference -8.09 (95% CI -12.57 to -3.61, Analysis 2.1) and
in neurological function (crude difference between mean scores at
the end of treatment -2.19 (95% CI -4.01 to -0.37, Analysis 2.4).
Psychotherapy
Depression data were available for three trials including 445 par-
ticipants (Lincoln 2003;Watkins 2007; Zhao 2004)with some ad-
ditional adverse event data available from one trial (Towle 1989).
No treatment effect was demonstrated on any of the endpoints
measured.
D I S C U S S I O N
Seven new trials, four of pharmacotherapy (five interventions,
Jiang 2001a; Lai 2006a; Ponzio 2001; Rampello 2005; Yang 2002)
and two of psychotherapy (Watkins 2007; Zhao 2004), meeting
our review criteria have become available since this review was
first published in 2004. The addition of the new pharmacother-
apy trials altered the results of the previous review and while there
is now some evidence to support the use of pharmacotherapy to
treat depression after stroke there is also stronger evidence of more
adverse events for those receiving antidepressants. The results of
this meta-analysis should also be considered in light of the recent
meta-analysis showing a small benefit of SSRIs only in those with
severe depression, with that benefit possibly being explained by
fewer in this group responding to placebo (Kirsch 2008). The ad-
dition of the psychotherapy trials (Watkins 2007; Zhao 2004) did
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not change the previous review finding that there is no evidence of
the effectiveness of psychotherapy for the treatment of depression
after stroke.
Unfortunately, the results of the trials in this review did not allow
for pooling of some key endpoints, so we have provided a predom-
inantly narrative review of the evidence. However, this evidence of
benefit must be considered alongside several basic methodological
limitations of many of these trials, including the short duration
of many interventions, variation in the types of trial participants
recruited and the methods used to diagnose depression, lack of an
a priori measurable endpoint, and the generally poor design, out-
come assessment, analysis and interpretation of results. Of particu-
lar concern is the evidence of harm (more adverse events) given the
small number of trials that systematically recorded and reported
adverse events, making reliable the assessment of the benefits and
risks of treatments impossible.
For pharmacotherapy trials, a key requirement is to achieve a ther-
apeutic dose of the medication for an adequate period of time.
The guidelines for the AmericanCollege of Physicians suggest that
antidepressants should be continued for at least four months be-
yond initial recovery, and that treatment should be changed if no
response has been shown by six weeks (Snow 2000). In this review,
the interventions in most pharmacotherapy trials were probably
not given for an adequate length of time to show a maximal or
sustained response. Therefore, we are unable to comment on the
long-term effects of antidepressant therapy, or provide informa-
tion on the most appropriate duration or dose of treatment, if one
group of antidepressants is more efficacious, or provide stopping
rules for antidepressant therapy in this group.
For psychotherapy trials, there is also good evidence that efficacy
is linked to delivery of an adequate exposure to the intervention.
This means that therapists should be trained and supervised in the
therapy they are delivering, and use a standardised, pre-specified,
framework for therapy. To achieve this in psychotherapy trials, the
therapy is determined using a manual and the research therapists
are trained and supervised in the use of the manual. Success in
brief therapy is linked to adherence to the therapeutic model as
well as to the therapists’ characteristics. Future stroke psychother-
apy trials should also adhere to these standard psychotherapy re-
search guidelines if there is to be any probability of demonstrating
consistency and response.
The trials in this review included participants with depression
occurring several days to more than two years following stroke.
However, depression occurring in the early phase of stroke is likely
to be different from that occurring several months or years after
the event. Survivors in the first weeks following stroke are coping
with the consequences of experiencing a potentially life-threaten-
ing event, as well as recovering from the disabling effects of the
stroke itself. In the medium to long-term, survivors of stroke are
more likely to be adjusting to the prospects of permanent disability
and changes in social and financial circumstances. It is difficult to
summarise the evidence from such mixed populations, and even
in doing so, whether it could be considered meaningful, especially
given the high risk of relapse of depression in the first few months
of recovery, which declines over time (Snow 2000).
In contrast to the wide range in the length of time between stroke
onset and entry into the trial, many trials included patients with
narrowdemographic and clinical characteristics, in particular, they
excluded patients with communication problems, cognitive loss,
or previous psychiatric illness. This reinforces a common criticism
of depression research, that the trial participants are not represen-
tative of those requiring treatment in the ’real world’ (Zimmerman
2002). It would appear that this criticism is also applicable to tri-
als of depression following stroke, where up to half of survivors
may be excluded using such criteria (Turner-Stokes 2003). Given
the high age of most patients with stroke, and the frequent pres-
ence of neurological impairments, aphasia and co-morbid medi-
cal conditions, the fact that up to half of all survivors of stroke
are excluded limits the external validity (generalisability) of the
results. The use of a large list of exclusions means that the re-
sults are applicable to only a small proportion of stroke survivors
who have a narrow range of co-morbidities and other characteris-
tics. Such exclusions may be justifiable for trials of psychotherapy,
where participants are required to actively participate in therapy
by talking, but seem inappropriate for the pharmacotherapy trials.
Ideally, patients should be heterogeneous with regard to stroke di-
agnosis, which requires the use of standard diagnostic criteria and
neuroimaging in a high proportion of cases. Given differences in
the natural history and management of SAH it could be argued
that this form of stroke should be examined separately.
The lack of a consistent method to diagnose depression, both for
entry and outcome, in the included trials is a concern and a re-
flection of the general lack of a standard definition for a ’healthy
state’ among people with mood disorders (Keller 2003). Few tri-
als stated whether the primary goal of therapy was remission (no
longer meeting the baseline criteria for depression), response (a
50% reduction in mood scores from baseline), or simply a greater
reduction in mood scores (or difference in scores) in one of the
randomised groups. The complete remission of symptoms is ar-
guably the most meaningful endpoint for the patient, whereas the
significance of a small reduction in mood scores on a continu-
ous scale is generally difficult to interpret for the patient and the
treating physician. These problems with outcome assessment were
further confounded by the frequent use of multiple scales both
between and within trials. Because multiple scales were used in
each trial, selective reporting of findings was also common. Any
one scale was used across only eight trials at most, and signifi-
cantly different cut-points were used to determine depression at
entry and trial end. Given the practical difficulties and high cost
of conducting psychiatric interviews in clinical trials it seems ap-
propriate to adopt a pragmatic approach to determine depression
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on the basis of a validated mood questionnaire or semi-structured
interview. Hopefully the compulsory registration of trial protocols
on publicly available databases will reduce, if not eliminate, the
opportunity for selective reporting of results. It has been suggested
that more than one third of efficacy outcomes and half of harm
outcomes are inadequately reported (Chan 2004).
Several other methodological deficiencies in trials further limit
the conclusions that can be drawn from this review. Many trials
were small, less than half reported adequate concealment of the
randomisation sequence, and drop-out rates were high in several
trials. One trial (Andersen 1994) excluded patients randomised
before 28 days from their analyses, co-incidentally this group of
patients experienced large responses in the placebo group. Addi-
tionally, blinding of investigators and outcome assessors was sel-
dom stated. Reporting and analysis of results varied, with most
(eight) trials presenting per-protocol analyses only or not speci-
fying whether analyses were per protocol or ITT. For trials with
high drop-out rates, ITT analysis of the data is very important.
Researchers need to specify how missing data are handled (Hollis
1999). If ITT (giving missing data both the best possible and
worst possible outcome) and per-protocol analysis indicate similar
trends, the findings are likely to be interpreted as being clinically
more robust. It continues to seem pertinent to recommend that
researchers consult the ICHHarmonised Tripartite Guidelines for
statistical principles for clinical trials (ICH 1999) and the revised
CONSORT guidelines (Moher 2003) when designing, and re-
porting findings of, future trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is evidence from trials in stroke patients to tentatively sup-
port the use of prescription antidepressants to treat depression but
this must be considered in light of the evidence of an associated
increase in harm and of a lack of efficacy of SSRIs generally except
in those with severe depression. Antidepressants may produce a
remission or a response in terms of lower scores on mood rating
scales, but also increase adverse events. It is recommended that
these agents are used with caution in those with a persistent de-
pressive disorder after stroke, as little is known about the risks,
especially of seizures, falls and delirium, especially in older people
and those on concomitant medication. We found no evidence for
the benefit of psychotherapy.
Implications for research
We recommend the need for further research in this area. Future
trials investigating the effect of pharmacotherapy and psychother-
apy in the treatment of depression in people after stroke should
address the following:
• review and refine the methods for trials of psychological
endpoints in people with physical illness;
• recruit an adequate number of participants so that variables
such as time passed between stroke and recruitment, and
inclusion of patients with dysphasia, and SAH can be controlled,
and modest but clinically important effects can be detected;
• recruit a representative ’real world’ sample of patients to
enable results to be generalised to the majority of stroke survivors;
• provide treatment for a sufficient duration and follow up, so
that rates of relapse or maintenance of remission can be assessed;
• psychotherapy interventions need to be carefully specified
and monitored;
• include careful, prospective assessment and complete
reporting of adverse events;
• define a priori an unambiguous, measurable, primary
endpoint;
• limit the number of secondary outcomes to three or four
and report results for all outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andersen 1994
Methods Parallel design
Method of randomisation: blocks of 4 used
Method of concealment: centralised, opaque envelopes
Blinding: double-blind reported, those blinded not stated
Analysis: ITT (last observation carried forward) and per protocol: death (1 treatment, 1 control), with-
drawn due to AE (6 treatment, 1 control), all excluded from analysis
Participants Location: Denmark
Setting: mixed
Treatment: 33 (36% male, mean age 68 years, SD 4)
Control: 33 (66% male, mean age 66 years, SD 9)
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage; diagnosis via clinical signs and
CT (100%); stroke 2 to 52 weeks prior to randomisation (average time 12 weeks)
Depression criteria: HDRS score > 12 (score transformed to appropriate DSM-III-R criteria)
Other entry criteria: none stated
Comparability of treatment groups: balanced
Interventions Treatment: citalopram, 10 mg in participants > 66 years, 20 mg in participants < 67 years, daily; dose
doubled if no response to treatment within 3 weeks
Control: matched placebo
Duration: treatment continued for 6 weeks
Outcomes Depression: change in scores from baseline to end of treatment on HDRS*
Melancholia Scale
Proportion no longer meeting entry criteria (< 13 on HDRS)
50% reduction in HDRS score
Additional: leaving the study early
Death
Adverse events
Unable to use: BI, Social Activities Index, MMSE (data not presented)
Notes Exclusion criteria: depression within last year, receiving current treatment for depression, severe dementia
or communication problems, degenerative or expansive neurological disease, decreased consciousness
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Fruehwald 2003
Methods Parallel design
Method of randomisation: permuted block design
Method of concealment: centralised
Blinding: double blind
Participants: yes
Relatives: yes
Clinical examiners: yes
Nursing staff: yes
Analysis: per protocol: death (1 treatment), withdrawn due to AE (1 treatment, 2 control), all excluded
from analysis
Participants Location: Austria
Setting: inpatients
Treatment: 28 (46% male, mean age 65 years, SD 14)
Control: 26 (71% male, mean age 64 years, SD 14)
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage; diagnosis via clinical signs and
CT (100%); stroke on average 11 days prior to randomisation
Depression criteria: psychiatric interview, HDRS score > 15
Other entry criteria: none stated
Comparability of treatment groups: non-significant trend towards more females and right-sided lesion
strokes in treatment group
Interventions Treatment: fluoxetine 20 mg, daily; dose escalation at 4 weeks if HDRS score > 13
Control: matched placebo
Duration: treatment continued for 12 weeks
Outcomes Depression: change in scores from baseline to end of treatment on HDRS, BDI and Clinical Global
Impression Scale (Item 1)
Proportion of responders (< 13 HDRS)
Additional: Scandinavian Stroke Scale
Death
Adverse events (selected data)
Unable to use: RS, BI, MMSE (data not presented at follow up)
Adverse events data on dizziness, nausea and cephalalgia (data not presented by group)
Notes Exclusion criteria: MMSE < 20, more than mild communication deficit, diseases of the CNS and previous
degenerative or expansive neurological disorders
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Jiang 2001a
Methods Parallel design
Method of randomisation: randomised stated, method unclear
Method of concealment: unclear
Blinding: single blind reported
Participants: yes
Investigators: no
Outcome assessors: unclear
Analysis: ITT (no drop outs)
Participants Location: China
Setting: inpatient
Treatment: 30 (57% male, mean age 62 years, SD 14)
Control: 15 (60% male, mean age 63 years, SD 15)
Stroke criteria: unclear, diagnosis via CT or MRI (100%); stroke 0 to 7 days prior to randomisation
Depression criteria: HDRS > 8
Other entry criteria: Chinese stroke scale score > 8, can independently complete assessment scale, aged <
80 years, no severe negative life events in past year, first stroke, no previous psychosis or antidepressant
medication
Comparability of treatment groups: intervention group younger, higher HDRS score and lower CSS score
Interventions Treatment: amitriptyline 50 mg increasing by 25 mg per day to 200 mg daily
Control**: placebo (not matched) two tablets per day
Duration: treatment continued for 6 months
Outcomes Depression: change in scores from baseline to end of treatment on HDRS
Additional: adverse events, CSS
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Jiang 2001b
Methods Parallel design
Method of randomisation: randomised stated, method unclear
Method of concealment: unclear
Blinding: single blind reported
Participants: yes
Investigators: no
Outcome assessors: unclear
Analysis: ITT
Participants Location: China
Setting: inpatient
Treatment: 30 (58% male, mean age 62 years, SD 14)
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Jiang 2001b (Continued)
Control: 15 (60% male, mean age 63 years, SD 15)
Stroke criteria: unclear, diagnosis via CT or MRI (100%); stroke 0 to 7 days prior to randomisation
Depression criteria: HDRS > 8
Other entry criteria: Chinese stroke scale score > 8, can independently complete assessment scale, aged <
80 years, no severe negative life events in past year, first stroke, no previous psychosis or antidepressant
medication
Comparability of treatment groups: intervention group younger, higher HDRS score and lower CSS score
Interventions Treatment: Deanxit 2 tablets daily
Control**: placebo (not matched but frequency matched)
Duration: treatment continued for 6 months
Outcomes Depression: change in scores from baseline to end of treatment on HDRS
Additional: adverse events, CSS
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Lai 2006a
Methods Parallel design
Method of randomisation: randomised stated, method unclear
Method of concealment: unclear
Blinding: unclear
Analysis: unclear
Participants Location: China
Setting: inpatients
Treatment: 40
Control: 40
(Total 54% male, mean age 60 years, SD 14)
Stroke criteria: unclear; diagnosis via CT; time from stroke to randomisation unclear
Depression criteria: HDRS score > 6
Other entry criteria: none stated
Comparability of treatment groups: unclear
Interventions Treatment: paroxetine 20 mg daily
Control: placebo
Duration: treatment continued for 2 months
Outcomes Depression: differences in mean scores on HDRS at end of treatment, 50% reduction in scores on HDRS
Additional: Scandinavian Stroke Scale
Death
Adverse events (selected data)
28Interventions for treating depression after stroke (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lai 2006a (Continued)
Unable to use: RS, BI, MMSE (data not presented at follow up)
Adverse events data on dizziness, nausea and cephalalgia (data not presented by group)
Notes Exclusion criteria: unclear
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Lincoln 2003
Methods Parallel design
Method of randomisation: computer-generated random number sequence
Method of concealment: opaque consecutively numbered sealed envelopes held by independent researcher
Blinding: single blind
Participants: no
Investigators: yes
Outcome assessors: yes
Analysis: per protocol: death (2 control), withdrew consent (1 control, 1 attention control, 1 treatment),
all excluded from analysis
Participants Location: UK
Setting: outpatients
Treatment: 39 (51% male, mean age 67 years, SD 13)
Attention controlˆ: 41 (51% male, mean age 66 years, SD 13)
Controlˆ: 41 (51% male, mean age 65 years, SD 15)
Stroke criteria: all subtypes; diagnosis via clinical signs and symptoms and CT (percentage not reported);
stroke 1 to 6 months prior to randomisation
Depression criteria: psychiatric interview (SCAN), BDI score > 10, WDI score > 18
Other entry criteria: none stated
Comparability of treatment groups: significantlymore participantswith an ICD-10 diagnosis of depression
in the treatment group
Interventions Treatment: cognitive behavioural therapy, including modification of unhelpful thoughts and beliefs (10 x
1 hour sessions over 13 weeks)
Attention control: no formal therapeutic intervention; conversation focused on day-to-day occurrences
and discussion regarding the physical effects of stroke and life changes (10 x 1 hour visits over 13 weeks)
Control: standard care (no contact)
Delivered by: community psychiatric nurse
Outcomes Depression: change in scores from baseline to end of treatment and end of follow up on BDI, WDI, GHQ
28*
Additional: Leaving the study early
Death
Extended ADL
Unable to use: adverse events (data not presented)
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Lincoln 2003 (Continued)
London Handicap Scale (no mean or SD presented)
Notes Exclusion criteria: blindness, deafness, participant did not speak English, dementia documented inmedical
records, treated for depression in previous 5 years, lived outside specified locality, participant could not
complete questionnaire unaided
Additional unpublished data provided by author
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Lipsey 1984
Methods Parallel design
Method of randomisation: random number table
Method of concealment: unclear
Blinding: double blind
Participants: yes
Families: yes
Clinical examiners: yes
Nursing staff: yes
Analysis: per protocol: withdrawn due to AE (3 treatment, 1 control), withdrew consent (1 control), all
excluded from analysis; After at least one week of treatment: withdrew due to AE (3 treatment, 1 control),
death (2 control), lost to follow-up (2 control), included in analyses using last observation carried forward
Participants Location: USA
Setting: mixed
Treatment: 17 (64% male, mean age 62 years, SD 9)
Control: 22 (65% male, mean age 60 years, SD 12)
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage; diagnosis via clinical signs and
CT (100%); stroke on average 262 +/- 437 days (treatment group) and 128 +/- 190 days (control group)
prior to randomisation
Depression criteria: psychiatric interview (PSE, DSM-III)
Other entry criteria: included outpatients who requested treatment for poststroke depressive disorder
Comparability of treatment groups: balanced
Interventions Treatment: nortriptyline 20 to 100 mg daily; 2 treatment regimens combined; dose escalation over treat-
ment period to 100 mg
Control: matched placebo
Duration: treatment continued for 4 to 6 weeks
Outcomes Depression: change in scores from baseline to end of treatment on HDRS and ZDS*,ˆ,†
Proportion no longer meeting entry criteria (DSM-III)
Additional: Leaving the study early
Death
Adverse events
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Lipsey 1984 (Continued)
Unable to use: PSE (modified by authors), MMSE, John Hopkins Functioning Inventory, Social Ties
Checklist (data not presented)
Notes Exclusion criteria: current treatment for depression, severe comprehension deficit, medical contraindica-
tion to nortriptyline
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Murray 2002
Methods Parallel design
Method of randomisation: block
Method of concealment: centralised
Blinding: double blind
Participants: yes
Relatives: yes
Clinical examiners: yes
Nursing staff: yes
Analysis: ITT (last observation carried forward) and per protocol: death (2 control), no efficacy (16
treatment, 22 control), withdrawn due to AE (8 treatment, 5 control), withdrew consent (1 control), all
excluded from analysis
Participants Location: Sweden
Setting: mixed
Treatment: 62 (52% male, mean age 71 years, SD 10)
Control: 61 (44% male, mean age 71 years, SD 10)
Stroke criteria: all subtypes, diagnosis via clinical signs and CT (100%); stroke 3 to 367 days prior to
randomisation (average time 128 days)
Depression criteria: psychiatric interview (DSM-IV, major and minor) and MADRS > 9
Other entry criteria: > 17 years of age, stroke within previous 12 months
Comparability of treatment groups: significant trend towards more left hemisphere lesion strokes in
treatment group
Interventions Treatment: sertraline 50 mg daily; possible dose escalation to 100 mg after 4 weeks
Control: matched placebo
Duration: treatment continued for 26 weeks
Outcomes Depression: change in scores from baseline to end of treatment on MADRS
Additional: Leaving the study early
Death
Unable to use: Scandinavian Stroke Scale, BI, Stroke UnitMental Status, Examination social performance,
treatment costs,mortality, relative’s situation, neuropsychological performance, neurological recovery (data
not presented)
Adverse events (selected data presented)
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Murray 2002 (Continued)
Notes Exclusion criteria: under 18 years of age, severely impaired communication, apparent difficulties in adher-
ing to study protocol, acute myocardial infarction, other psychiatric illness other than depression, signifi-
cant risk of suicide, antidepressants during the month before randomisation, current use of psychotropic
medication or opiate analgesic drugs
Participants with less than 20% reduction in MADRS score at 6 weeks were excluded
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Ohtomo 1991
Methods Parallel design
Method of randomisation: randomised stated, method unclear
Method of concealment: unclear
Blinding: double blind reported, those blinded not stated
Analysis: unclear
Participants Location: Japan
Setting: unclear
Treatment: 150 (details unclear)
Control: 135 (details unclear)
Stroke criteria: ischaemic stroke; method of diagnosis unclear; time from stroke to randomisation unclear
Depression criteria: based on physician’s impression, no scale was used for evaluation
Other entry criteria: none stated
Comparability of treatment groups: unclear
Interventions Treatment: aniracetam 600 mg twice daily
Control: matched placebo
Duration: treatment continued for 12 weeks
Outcomes Depression: physician assessment of change in depression from baseline to end of treatment
Additional: physician assessment of change in anxiety
Unable to use: Leaving the study early (data not presented)
Death (data not presented)
Adverse events (data not presented)
Notes Exclusion criteria: unclear
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Ponzio 2001
Methods Parallel design
Method of randomisation: randomised stated, method unclear
Method of concealment: unclear
Blinding: double blind reported, those blinded not stated
Analysis: ITT
Participants Location: Italy
Setting: outpatient
Treatment: 112 (54% male, mean age 64 years, SD 11)
Control: 117 (55% male, mean age 66 years, SD 11)
Stroke criteria: unclear; method of diagnosis unclear; time from stroke to randomisation unclear
Depression criteria: MADRS > 18
Other entry criteria: 18 to 85 years of age, MMSE score > 23
Comparability of treatment groups: balanced
Interventions Treatment: paroxetine 20 to 40 mg daily
Control: matched placebo
Duration: treatment continued for 8 weeks
Outcomes Depression: change in scores from baseline to end of treatment on MADRS, CGI
Additional: Proportion scoring < 7 on MADRS and responders on CGI
Change in Rankin and BI scores from baseline to end of treatment
Adverse events
Notes Exclusion criteria: concurrent predominant psychiatric disorders, psychotropic pharmacotherapy, sub-
stance abuse/dependence, participation in other clinical trials, suicide risk, concomitant medication, in-
tolerance to paroxetine
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Rampello 2005
Methods Parallel design
Method of randomisation: computer generated code number
Method of concealment: code disclosed on box.
Blinding: double blind
Participants: yes
Investigators: yes (had potential for being unblinded)
Outcome assessor: no
Analysis: unclear; no-one withdrew from the study
Participants Location: Italy
Setting: outpatient
Treatment: 16 (44% male, mean age 78 years, SD 4)
Control: 15 (46% male, mean age 77 years, SD 4)
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Rampello 2005 (Continued)
Stroke criteria: single ischaemic or hemorrhagic stroke; diagnosis via CT and MRI; stroke less than 12
months prior to randomisation
Depresion criteria: psychiatric interview, HDRS > 20, BDI > 15
Other entry criteria: presence of major or minor depression, presence of retarded depression, lack of
treatment with antidepressants 2 weeks prior to randomisation, absence of treatment with neuroleptic
drugs during 3 months before enrolment, informed consent
Comparability of treatment groups: balanced
Interventions Treatment: reboxetine 4 mg twice daily
Control: matched placebo
Duration: treatment continued for 16 weeks
Outcomes Depression: change in scores from baseline to end of treatment on HDRS* and BDI*
Additional: Adverse events
Unable to use: adverse event (data presented in a suitable format for this review)
Notes Exclusion criteria: previous degenerative or expansive neurologic disease, tumours, multiple sclerosis,
amyotrophic sclerosis, hydrocephalus, SAH, Binswanger’s disease, history of psychiatric illness (other than
depression), severe aphasia, severe cognitive deficit, chronic alcoholism
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Reding 1986
Methods Parallel design
Method of randomisation: random number table
Method of concealment: unclear
Blinding: double blind
Participants: yes
Treating physician: yes
Analysis: ITT (no drop-outs apparent)
Participants Location: USA
Setting: inpatients
Treatment: 11 (66% male, mean age 68 years, SE 2)
Control: 6 (73% male, mean age 68 years, SE 3)
Stroke criteria: all subtypes; diagnosis via clinical signs and CT (% not reported); stroke on average 45 +/
- 5 days (treatment group) and 48 +/- 13 days (control group) prior to randomisation
Depression criteria: psychiatric interview (DSM-III, major and minor)
Other entry criteria: none stated
Comparability of treatment groups: unclear
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Reding 1986 (Continued)
Interventions Treatment: trazodone-HCl 50 mg daily; dose escalation every 3 days to target dose of 200 mg
Control: matched placebo
Duration: treatment continued for 32 +/- 6 days (treatment group) and 24 +/- 4 days (control group)
Outcomes Depression: clinical diagnosis of depression
Additional: BI
Unable to use: clinical diagnosis of depression, ZDS, death (data not presented)
Leaving the study early
Adverse events (data not presented by group)
Notes Exclusion criteria: myocardial infarction within previous month, antiarrhythmic medication
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Towle 1989
Methods Parallel design
Method of randomisation: random number tables
Method of concealment: sealed envelopes held by secretary
Blinding: single blind
Participants: no
Investigators: no
Outcome assessor: yes
Analysis: per protocol: withdrew consent (1 control), excluded from analysis
Participants Location: UK
Setting: outpatients
Treatment: 21 (43% male, mean age 70 years, SD 9)
Control: 23 (30% male, mean age 69 years, SD 7)
Stroke criteria: all subtypes; diagnosis via clinical signs; stroke on average 25 +/- 7 months (treatment
group) and 25 +/- 6 months (control group) prior to randomisation
Depression criteria: WDI score > 17 or GHQ-28 score > 9
Other entry criteria: able to complete questionnaires unaided
Comparability of treatment groups: demographically balanced, treatment group reported more social
dysfunction on GHQ-28
Interventions Treatment: pragmatic approach dealing with problems identified by social worker and the patients; in-
cluded counselling the patient and caregiver, giving opportunity to reflect upon their situation and express
their feelings (duration: 2 to11 visits over 16 weeks, mean number visits 6.8 +/- 2.8)
Control: custom designed information booklet, 1 visit, no ongoing visits
Delivered by: social worker
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Towle 1989 (Continued)
Outcomes Depression: change in scores from baseline to end of treatment on WDI, GHQ-28, proportion no longer
meeting entry criteria
Additional: Leaving the study early
Unable to use: WDI, GHQ-28, Extended ADL, FAI, services questionnaire, Life Satisfaction Index,
Nottingham Health Profile (data presented as median and range)
Death
Adverse events (data not presented)
Notes Exclusion criteria: stroke < 1 year prior to randomisation, residence in hospital or residential care
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Watkins 2007
Methods Parallel design
Method of randomisation: computer package minimizing for age, sex, baseline BI score, stay on acute
stroke unit; therapist assignment by opaque envelope
Method of concealment: computer program for initial randomisation, opaque envelope for therapist
Blinding: open trial
Analysis: ITT (hot deck imputation), death (3 treatment, 8 control)
Participants Location: UK
Setting: inpatient
Treatment: 127 (52% male, mean age 68 years, SD 12)
Control: 127 (53% male, mean age 68 years, SD 12)
Stroke criteria: all subtypes; diagnosis via clinical signs and CT (100%); stroke 5 to 28 days prior to
randomisation
Depression criteria: GHQ score > 4
Other entry criteria: over 18 years
Comparability of treatment groups: balanced
Interventions Treatment: motivational interviewing, up to 4 sessions, 1 per week, with same therapist
Control: usual care
Delivered by: nurses and non-clinical psychologists
Outcomes Depression: no longer meeting study criteria for depression on GHQ-28, change in scores from baseline
to end of treatment on GHQ-28
Additional: Yale, BI, Stroke Expectations Questionnaire
Notes Exclusion criteria: severe cognitive and communication problems, moving out of the area after discharge,
already receiving psychiatric or clinical psychology intervention
Additional unpublished data provided by authors
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Watkins 2007 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Wiart 2000
Methods Parallel design
Method of randomisation: randomised stated, method unclear
Method of concealment: unclear
Blinding: double blind reported, those blinded not stated
Analysis: ITT (last observation carried forward), withdrawn due to AE (1 treatment), protocol violation
(1 treatment)
Participants Location: France
Setting: unclear
Treatment: 16 (56% male, mean age 66 years, SD 7)
Control: 15 (40% male, mean age 69 years, SD 12)
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage; diagnosis via clinical signs and
CT (100%); stroke on average 47 +/- 22 days (treatment group) and 48 +/- 20 days (control group) prior
to randomisation
Depression criteria: psychiatric interview (ICD-10 criteria) and MADRS score > 19
Other entry criteria: all antidepressant or neuroleptic drugs stopped 10 days prior to enrolment
Comparability of treatment groups: balanced
Interventions Treatment: fluoxetine 20 mg daily
Control: matched placebo
Duration: treatment continued for 45 days
Outcomes Depression: change in scores from baseline to end of treatment on MADRS, 50% reduction in MADRS
score
Additional: Functional Independence Measure
MMSE
Motoricity Index
Leaving the study early
Death
Adverse events
Notes Exclusion criteria: severe psychiatric problemswhich required hospitalisation, severe cognitive impairment,
chronic alcoholism, chronic associated handicapping pathology, contraindication to fluoxetine
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Yang 2002
Methods Parallel design
Method of randomisation: randomised stated, method unclear
Method of concealment: unclear
Blinding: unclear
Analysis: unclear, withdrawn due to AE (4 treatment, 7 control)
Participants Location: China
Setting: outpatient
Treatment: 64 (63% male, mean age 64 years, SD 3)
Control: 57 (56% male, mean age 63 years, SD 5)
Stroke criteria: ischaemic and haemorrhagic stroke; diagnosis unclear; stroke range 1.5 to 6 months prior
to randomisation
Depression criteria: HDRS score > 7
Other entry criteria: unclear
Comparability of treatment groups: balanced
Interventions Treatment: paroxetine 20 mg daily
Control: matched placebo
Duration: treatment continued for 4 months
Outcomes Depression: 50% reduction in scores from baseline to end of treatment on HDRS
Additional: cured: defined as scoring < 7 in 2 consecutive weeks (unable to use as timing of these 2 weeks
not stated)
Notes Exclusion criteria: unclear
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Zhao 2004
Methods Parallel design
Method of randomisation: randomised stated,method unclear, but stratified by age, sex and stroke subtype
Method of concealment: unclear
Blinding: unclear
Analysis: unclear
Participants Location: China
Setting: inpatient
Treatment: 35 (57% male, mean age 65 years, SD 13)
Control: 35 (51% male, mean age 61 years, SD 14)
Stroke criteria: unclear; diagnosis via CT or MRI (100%); stroke range to randomisation, unclear
Depression criteria: HDRS score > 17
Other entry criteria: cognitively competent, no acute medical problems
Comparability of treatment groups: balanced
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Interventions Treatment: psycho-education, daily, less than 30 minutes
Control: usual care
Duration: treatment continued for 4 weeks
Delivered by: special personnel
Outcomes Depression: reduction in scores from baseline to end of treatment on HDRS*
Notes Exclusion criteria: unclear
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
*: Change scores calculated by review authors from available data
** Results for control group halved
ˆ: Results for attention-control and control group pooled
ˆˆ: Standard deviation of mean scores calculated from standard errors by review authors
†: Mean and standard deviation scores extrapolated from figures in paper
ADL: activities of daily living
AE: adverse event(s)
BDI: Beck Depression Inventory
CSS: Chinese Stroke Scale
CT: computed tomography
BI: Barthel Index
DSM: Diagnostic Scientific Manual
FAI: Frenchay Activities Index
FAST: Frenchay Aphasia Screening Test
GDS: Geriatric Depression Scale
GHQ: General Health Questionnaire
HARS: Hamilton Anxiety Rating Scale
HDRS: Hamilton Depression Rating Scale
HRQoL: Health Related Quality of Life
ICD: International Classification of Diseases
ITT: intention to treat
MADRS: Montgomery Asberg Depression Rating Scale
MMSE: Mini-Mental State Examination
PSE: Present State Examination
RS: Rankin Scale
SD: standard deviation
SE: standard error
WDI: Wakefield Depression Inventory
ZDS: Zung Depression Scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agnoli 1985 Allocation: randomised
Participants: chronic cerebrovascular disease: unable to isolate stroke patients
Aizawa 1986 Allocation: randomised
Participants: cerebrovascular disorders
Interventions: no placebo comparison
Balunov 1990 Allocation: randomised
Participants: poststroke depression
Interventions: no placebo comparison
Bao 2001 Allocation: nnclear
Participants: post stroke
Interventions: some patients in the intervention group received antidepressants, no one in the control group
did
Battaglia 1999 Allocation: randomised
Participants: post stroke
Interventions: Nno placebo comparison
Battaglia 2001 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Bautz-Holter 2002 Allocation: randomised
Participants: post stroke
Interventions: early supported discharge, did not meet review criteria, not structured or timetabled as a talking
therapy
Berrol 1997 Allocation: random
Participants: post stroke
Intervention: dance/movement therapy, did not meet review criteria
Casella 1960 Allocation: quasi randomised
Participants: hemiplegia, unable to isolate stroke
Interventions: iproniazid
Outcome: depression not primary endpoint
Chen 2001 Allocation: randomised
Participants: post stroke
Interventions: fluoxetine, no placebo control (routine care)
Chen 2002 Allocation: randomised
Participants: post stroke
Interventions: fluoxetine, doxepine, vitamin B6, no placebo control
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Chen 2005 Allocation: randomised
Participants: post stroke
Interventions: citalopram or fluoxetine, no placebo control (activating blood circulation and rehabilitation)
Chen 2005a Allocation: randomised
Participants: post stroke
Interventions: repetitive transcranial magnetic stimulation not meeting review criteria
Cheng 2003 Allocation: randomised
Participants: post stroke
Interventions: fluoxetine, no placebo control arm (routine care)
Cheng 2003a Allocation: unclear
Participants: post stroke
Interventions: fluoxetine, no placebo control (routine care)
Choi-Kwon 2006 Allocation: randomised
Participants: post stroke
Interventions: fluoxetine, treatment trial for depression, emotionalism and anger
Outcome: data not available in depressed and not depressed with proportions, mean scores and standard
deviations
Christie 1984 Allocation: randomised
Participants: post stroke
Interventions: social work, did not meet review criteria, not structured or timetabled as a talking therapy
Corr 1995 Allocation: randomised
Participants: post stroke
Interventions: rehabilitation, did not meet review criteria, not structured or timetabled as a talking therapy
Corr 2004 Allocation: randomised
Participants: post stroke
Interventions: cross-over study design. No drug or psychological intervention involved
Cui 2001 Allocation: not randomised
Participants: post stroke
Intervention: no placebo comparison
Cullum 2007 Allocation: randomised
Participants: older medical patients including stroke
Intervention: liaison psychiatric nurse + care plan including psychotherapy and/or antidepressents, not meet
review criteria
Davis 1997 Allocation: randomised
Participants: post stroke
Interventions: life review therapy
Outcome: therapy did not develop social problem solving skills or adjustment to stroke, did not meet review
criteria
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Dennis 1997 Allocation: randomised
Participants: post stroke
Interventions: stroke family careworker, did not meet review criteria, not structured or timetabled as a talking
therapy
Dennis 2000 Allocation: randomised
Participants: post stroke
Interventions: stroke family careworker, did not meet review criteria, not structured or timetabled as a talking
therapy
Desrosiers 2007 Allocation: unclear
Participants: post stroke
Intervention: leisure education programme, did not meet review criteria
Dong 2007 Allocation: randomised
Participants: post stroke
Intervention: electroacupuncture, western medicine, did not meet review criteria
Downes 1995 Allocation: tandomised
Participants: post stroke
Interventions: Egan’s problem solving therapy
Outcome: data not currently available
Drummond 1995 Allocation: randomised
Participants: post stroke
Interventions: leisure rehabilitation, did not meet review criteria, not structured or timetabled as a talking
therapy
Du 2005 Allocation: randomised
Participants: post stroke
Interventions: repetitive transcranial magnetic stimulation not meeting review criteria
Evans 1997 Allocation: randomised
Participants: acute geriatric medical inpatients with depression, unable to isolate any chronic stroke patients
No acute stroke patients included in sample
Feng 2004 Allocation: random
Participants: post stroke
Intervention: fluoxetine, jieyu huoxue decoction, no placebo control
Feng 2005 Allocation: randomised
Participants: post stroke
Intervention: psychotherapy intervenion inlcudes exercise therapy which wasn’t included in the control group
Fengqi 2003 Allocation: randomised
Participants: post stroke
Interventions: yukangning - traditional Chinese medicine, no placebo comparison
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FX Project 1976 Allocation: randomised
Participants: cerebrovascular diseases, those with stroke unable to be isolated
Gekht 2002 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Gekht 2003 Allocation: not randomised, ’divided’
Participants: post stroke
Interventions: no placebo comparison
Goh 2001 Allocation: randomised
Participants: post stroke
Interventions: music therapy, did not meet review criteria, not structured or timetabled as a talking therapy
Gonzalez-T 1995 Allocation: quasi randomised
Participants: depressed post stroke
Interventions: no placebo comparison
Graffagnino 2003 Allocation: randomised
Participants: post stroke
Interventions: sertraline with matched placebo
Outcomes: data not currently available
Green 2002 Allocation: randomised
Participants: post stroke
Interventions: physiotherapy, did not meet review criteria, not structured or timetabled as a talking therapy
Guan 2003 Allocation: randomised
Participants: post stroke
Interventions: fluoxetine, levodopa, no placebo control
Guan 2004 Allocation: random
Participants: post stroke
Interventions: patients in the intervention group received fluoxetine, no one in the control group did
He 2001 Allocation: randomised
Participants: post stroke
Interventions: combined Chinese antidepressants and psychotherapy with no placebo control
He 2003 Allocation: random
Participants: post stroke
Interventions: combined psychotherapy with amitriptyline, no placebo control
He 2004 Allocation: quasi randomised
Participants: post stroke
Interventions: fluoxetine, no placebo control
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He 2005 Allocation: randomised
Participants: post stroke
Interventions: paroxetine and psychotherapy, no placebo control, only a usual care arm
Hindle 2007 Allocation: randomised
Participants: post stroke
Interventions: sertraline
Outcomes: trial not completed
Hogg 1985 Allocation: randomised
Participants: post stroke
Interventions: acupressure versus therapeutic touch, no placebo control, intervention not meet review criteria
Hong 2004 Allocation: randomised
Participants: post stroke
Interventions: yuxingchangzhi tang and fluoxetine, no placebo control
House 2005 Allocation: randomised
Participants: post stroke
Intervention: SSRI
Trial not completed due to recruitment problems
Hu 2002 Allocation: randomised
Participants: post stroke
Intervention: fluoxetine, no placebo control
Hu 2005 Allocation: randomised
Participants: post stroke
Interventions: psychotherapy combined with fluoxetine, no placebo control
Huang 2001 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Huang 2004 Allocation: random
Participants: post stroke
Interventions: acupuncture, amitriptyline, no placebo comparison
Hui 1995 Allocation: randomised
Participants: post stroke
Interventions: medical management, did not meet criteria, not structured or timetabled as a talking therapy
Isenberg 2000 Allocation: unclear
Participants: post stroke
Interventions: nefiracetam
Outcomes: dta not currently available
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Ji 2000 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Jia 2005 Allocation: random
Participants: post stroke
Interventions: fluoxetine, no placebo control
Johnson 2000 Allocation: randomised
Participants: post stroke
Interventions: group/class education, did not meet review criteria, not structured or timetabled as a talking
therapy
Jongbloed 1991 Allocation: randomised
Participants: post stroke
Interventions: occupational leisure therapy, did not meet review criteria, not structured or timetabled as a
talking therapy
Jorge 2004 Allocation: randomised
Participants: post stroke
Interventions: transcranial magnetic stimulation, did not meet review criteria
Joubert 2006 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Juby 1996 Allocation: randomised
Participants: post stroke
Interventions: medical management, did not meet review criteria, not structured or timetabled as a talking
therapy
Kendall 2007 Allocation: randomised
Participants: post stroke
Interventions: primarily education and not delivered by somebody with explicitly stated training and super-
vision in therapies
Kwon 2003 Allocation: quasi randomised
Participants: post stroke
Interventions: taping/physiological, did not meet review criteria
Lai 2006b Allocation: randomised
Participants: post stroke
Interventions: physical exercise program - did not meet review criteria
Laska 2005 Allocation: randomised
Participants: acute stroke with aphasia
Interventions: moclobemide
Outcome: aphasia
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Lauritzen 1994 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Lee 2005 Allocation: unclear
Participants: post stroke
Interventions: repetitive transcranial magnetic stimulation, does not meet review criteria
Lehmann 2001 Allocation: randomised
Participants: post stroke
Interventions: imipramine, piracetam,versus usual care, no placebo comparison
Leijon 1989 Allocation: randomised
Participants: post stroke
Interventions: amitriptyline and carbamazepine
Outcome: pain
Li 1994 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Li 1999 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Li 2000 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Li 2002 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison (paroxetine versus traditional Chinese medicine)
Li 2004 Allocation: randomised
Participants: post stroke
Interventions: fluoxetine versus usual care, no placebo comparison
Li 2004a Allocation: random
Participants: post stroke
Interventions: antidepressant + activities of daily living training + psychotherapy + early rehabilitation, does
not meet review criteria
Li 2004b Allocation: random
Participants: post stroke
Interventions: psychotherapy + antidepressant (unspecified) versus usual care, no placebo comparison
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Li 2004c Allocation: random
Participants: post stroke
Interventions: antidepressants (unspecified) versus usual care, no placebo comparison
Li 2004d Allocation: unclear
Participants: post stroke
Interventions: patients in the intervention group received antidepressants, no one in the control group did
Li 2005 Allocation: randomised
Participants: post stroke
Interventions: doxepin hydrochloride no placebo control
Liang 2003 Allocation: randomised
Participants: post stroke
Interventions: fluoxetine, no placebo comparison
Liang 2005 Allocation: randomised
Participants: post stroke
Interventions: no placebo control
Liborio 2002 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Lin 2005 Allocation: randomised
Participants: post stroke
Interventions: psychotherapy and/or antidepressant care, no placebo control
Lincoln 1985 Allocation: randomised
Participants: post stroke
Interventions: speech therapy, did not meet review criteria, not structured or timetabled as a talking therapy
Liu 2003 Allocation: unclear
Participants: silent stroke (not meet review criteria)
Interventions: antidepressant + psychological intervention (not meet review criteria)
Liu 2003a Allocation: unclear
Participants: post stroke
Interventions: fastigial nucleus electrical stimulation + antidepressant therapy (not meet review criteria) versus
routine drug (unspecified) versus control, no placebo control group
Liu 2006 Allocation: randomised
Participants: post stroke
Interventions: yu le shu, fluoxetine, no placebo control
Liu 2006a Allocation: randomised
Participants: post stroke
Interventions: fluoxetine and acup-moxibustion, no placebo comparison
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Liu 2006b Allocation: randomised
Participants: post stroke
Interventions: citalopram versus amitriptyline, no placebo comaprison
Lu 2005 Allocation: randomised
Participants: diabetic patients post stroke
Interventions: cognitive therapy + electromyographic feedback + medication (not meet criteria) versus usual
care
Mant 1998 Allocation: randomised
Participants: post stroke
Interventions: information pack, did not meet review criteria, not structured or timetabled as a talking therapy
Mant 2000 Allocation: randomised
Participants: post stroke
Interventions: family support, did not meet review criteria, not structured or timetabled as a talking therapy
Martucci 1986 Allocation: randomised
Participants: unable to isolate people with stroke
Mauri 1988 Allocation: randomised
Participants: post stroke
Interventions: mianserin vs placebo
Outcomes: not available in a format appropriate for this review
Meara 1998 Allocation: randomised
Participants: post stroke
Interventions: sertraline with matched placebo for 6 weeks
Outcome: data not currently available
Meng 1996 Allocation: unclear
Participants: post stroke
Interventions: mi-an-she-lin versus amitriptyline, no placebo control
Miao 2004 Allocation: random
Participants: post stroke
Interventions: citalopram versus usual care, no placebo control
Min 2002 Allocation: randomised
Participants: post stroke
Interventions: no placebo control (control group received physcological rehabilitation therapy)
Min 2002a Allocation: randomised
Participants: post stroke
Interventions: antidepressant versus psychological therapy, no placebo or usual care comparison
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Miyai 1998 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Niedermaier 2004 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Nir 2004 Allocation: randomised
Participants: post stroke
Interventions: not talking therapy or sufficient training or supervision of ’therapists’
Nour 2002 Allocation: randomised
Participants: post stroke
Interventions: home leisure educational programme, not meet review criteria, not structured or timetabled as
a talking therapy
Ohtomo 1985 Allocation: randomised
Participants: post stroke
Interventions: tiapride with matched placebo for 6 weeks
Outcome: data not currently available
Ostwald 2006 Allocation: randomised
Participants: post stroke patients and carers
Interventions: no usual care comparison
Rampello 2004 Allocation: randomised
Participants: post stroke
Interventions: citalopram or reboxetine, no placebo control
Ricauda 2004 Allocation: unclear
Participants: post stroke
Interventions: home hospitalisation service, does not meet review criteria
Roberts 1995 Allocation: randomised
Participants: chronic illness
Interventions: no placebo comparison
Rodgers 1999 Allocation: randomised
Participants: post stroke
Interventions: stroke education, did not meet review criteria, not structured or timetabled as a talking therapy
Rudd 1997 Allocation: randomised
Participants: post stroke
Interventions: early hospital discharge, did not meet review criteria, not structured or timetabled as a talking
therapy
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Rønning 1998 Allocation: randomised
Participants: post stroke
Interventions: subacute rehabilitation, did not meet review criteria, not structured or timetabled as a talking
therapy
Sandberg 2001 Allocation: randomised
Participants: post stroke
Interventions: cPAP, did not meet review criteria
Seliger 1990 Allocation: not randomised
Participants: post stroke and multiple sclerosis
Interventions: no placebo comparison
Shan 2001 Allocation: randomised
Participants: post stroke
Interventions: fluoxetine versus acetamidepyrrolidone, no placebo control
Sivenius 2001 Allocation: randomised
Participants: acute post stroke
Interventions: did not meet review criteria (acute treatment)
Outcome: depression not primary endpoint
Smedley 1986 Allocation: randomised
Participants: post stroke
Interventions: slot machines, did not meet review criteria
Smith 2004 Allocation: randomised
Participants: post stroke (combined depressed and not depressed)
Intervention: education, did not meet review criteria
Song 1999 Allocation: randomised
Participants: post stroke
Interventions: scalp acupuncture, did not meet review criteria
Su 2004 Allocation: randomised
Participants: post stroke
Interventions: rehabilitation plus psychotherapy versus rehabilitation but rehabilitation includes fluoxetine
Sulch 2000 Allocation: randomised
Participants: post stroke
Interventions: integrated managed care pathway, did not meet review criteria, not structured or timetabled as
a talking therapy
Sulch 2002 Allocation: randomised
Participants: post stroke
Interventions: integrated managed care pathway, did not meet review criteria, not structured or timetabled as
a talking therapy
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Suskin 2006 Allocation: randomised
Participants: post stroke or transient ischaemic attack
Interventions: cardiac rehabilitation, not meet review criteria
Suzuki 2001 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Tan 2004 Allocation: unclear
Participants: post stroke
Interventions: provide comfortable environment, nutrition andmedication instruction, rehabilitation training
and education, did not meet review criteria
Taragano 2001 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison (both groups received fluoxetine, half received additional nimodipine,
half additional placebo)
Wade 1992 Allocation: randomised
Participants: post stroke
Interventions: physiotherapy, did not meet review criteria, not structured or timetabled as a talking therapy
Walker-Batson 1995 Allocation: randomised
Participants: post stroke
Interventions: dextroamphetamine versus placebo paired with physical therapy
Outcome: not depression
Walsh 1999 Allocation: unclear
Participants: post stroke
Interventions: relaxation versus aromatherapy versus reflexology versus aromatherapy + reflexology, not meet
review criteria
Wang 2002 Allocation: random
Participants: post stroke
Interventions: yukangning versus usual care, no placebo control
Wang 2003 Allocation: unclear
Participants: post stroke
Interventions: prozac versus amitriptyline versus usual care, no placebo comparison
Wang 2004 Allocation: randomised
Participants: post stroke
Interventions: paroxetine, no placebo control
Wang 2007 Allocation: randomised
Participants: post stroke
Interventions: yiyu, routine care + neurstan, no placebo control
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Werner 1996 Allocation: randomised
Participants: post stroke
Interventions: outpatient rehabilitation, did not meet review criteria, not structured or timetabled as a talking
therapy
Wheeler 2003 Allocation: unclear
Participants: post stroke
Interventions: music therapy, not meet review criteria
Wiart 1997 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Williams 2002 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Wolfe 2000 Allocation: randomised
Participants: post stroke
Interventions: community based rehabilitation, did not meet review criteria, not structured or timetabled as
a talking therapy
Wu 2002 Allocation: random
Participants: post stroke
Interventions: fluoxetine plus usual care versus usual care, no placebo comparison
Xia 2003 Allocation: random
Participants: post stroke
Interventions: some patients in the intervention group received antidepressants, no one in the control group
did
Xiaoying 2001 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison for antidepressants
Xie 2003 Allocation: unclear
Participants: post stroke but unclear whether includes only depressed, or mixed patients
Interventions: psychological intervention: feeling support therapy, recognition therapy, collective therapy,
social support and skills training
Xie 2005 Allocation: randomised
Participants: post stroke
Interventions: sertraline, no placebo control
Xing 1999 Allocation: random
Participants: post stroke
Interventions: fluoxetine plus routine drug therapy and rehabilitation versus routine drug therapy and reha-
bilitation, no placebo
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Xu 2001 Allocation: random
Participants: post stroke
Interventions: fluoxetine, rehabilitation, neurological drugs and psychotherapy versus rehabilitation, neuro-
logical drugs and psychotherapy, no placebo control
Ye 2004 Allocation: random
Participants: post stroke
Interventions: paroxetine versus imipramine versus usual care, no placebo comparison
Yi 1990 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Yokokawa 1991 Allocation: randomised
Participants: post stroke
Interventions: physical activity, did not meet review criteria, not structured or timetabled as a talking therapy
Yoneyama 1993 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
You 2002 Allocation: randomised
Participants: post stroke
Interventions: rehabilitation plus antidepressant versus rehabilitation versus drug therapy alone, no placebo
control
Young 1992 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Yu 1991 Allocation: unclear
Participants: post stroke (some)
Interventions: prompted toileting + social reinforcement versus control, not meet review criteria
Zhang 2000 Allocation: unclear
Participants: post stroke
Interventions: psychological therapy plus paroxetine versus psychological therapy
Zhang 2002 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Zhang 2002a Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
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Zhang 2002b Allocation: randomised
Participants: post stroke
Interventions: fluoxetine plus usual care versus usual care, no placebo comparison
Zhang 2005 Allocation: random
Participants: post stroke
Interventions: buspirone hydrocholride versus usual care, no placebo comparison
Zhang 2005a Allocation: randomised
Participants: post stroke
Interventions: acupuncture versus fluoxetine, no placebo comparison
Zhao 1999 Allocation: randomised
Participants: post stroke
Interventions: no placebo comparison
Zhao 2005 Allocation: random
Participants: post stroke
Interventions: citalopram versus venlafaxing, no placebo comparison
Zhao 2005a Allocation: randomised
Participants: post stroke
Interventions: citalopram versus amitriptyline, no placebo comparison
Zhou 2003 Allocation: unclear
Participants: post stroke
Interventions: fluoxetine and rehabilitation training, no placebo comparison
Zhou 2004 Allocation: random
Participants: post stroke
Interventions: therapist (not defined, no training or supervision stated) led strategy involving lots of people
including family and a buddy system
Zhu 2002 Allocation: random
Participants: post stroke
Interventions: fluoxetine plus usual care versus usual care, no placebo comparison
Zifko 2002 Allocation: not randomised
Participants: post stroke
Interventions: no placebo comparison
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Characteristics of ongoing studies [ordered by study ID]
Graven 2008
Trial name or title Parallel design
Method of randomisation: computer generated randomisation table
Method of concealment: sealed opaque envelopes
Blinding
Participants: yes
Outcome assessors: yes
Statisticians: yes
Methods
Participants Location: Australia
Setting: unclear
Stroke criteria: ischaemic and haemorrhagic stroke
Other entry criteria: unclear
Interventions Treatment: rehabilitation, goal setting, problem solving, facilitated referral to services, promotion of health
lifestyle, self efficacy and self reliance
Control: active control, usual care plus phone contact with allied health professional three times for support
and encouragement
Duration: treatment duration: minimum of 4, maximum of 12
Outcomes Depression: Geriatric Depression Scale
Starting date 2008
Contact information Christine Graven
Physiotherapy Department
St. Vincent’s Health Melbourne
PO Box 2900
Fitzroy 3065
Victoria
Tel: +61 3 9288 3927
Christine.GRAVEN@svhm.org.au
Notes Exclusion criteria: unclear
Mitchell 2002
Trial name or title Parallel design
Method of randomisation: unclear
Method of concealment: unclear
Blinding: single blind
Methods
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Participants Location: USA
Setting: unclear
Stroke criteria: ischaemic stroke
Other entry criteria: stroke within 4 months, 21 years of age and above
Interventions Treatment: cognitive behavioral therapy plus problem-solving
Control: active control, standard antidepressant treatment and written material
Duration: treatment duration: 9 sessions over 7 weeks
Outcomes Depression: HDRS
Starting date March 2002
Contact information Pamela H Mitchell
University of Washington
Seattle
Washington 98195-7266
USA
Notes Exclusion criteria: subarachnoid or intracranial hemorrhagic stroke, global aphasia, reduced level of con-
sciousness (GCS < 15)
NCT00194454
Thomas 2007
Trial name or title Parallel design
Method of randomisation: unclear
Method of concealment: unclear
Blinding: unclear
Methods
Participants Location: UK
Setting: unclear
Stroke criteria: unclear
Interventions Treatment 1: behavioural psychotherapy
Control 1: attention control
Control 2: no intervention
Duration: unclear
Outcomes Depression: unclear
Starting date April 2005
Contact information Miss Shirley Thomas
Research Associate
Division of Rehabilitation and Ageing
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Thomas 2007 (Continued)
B Floor Medical School
Queens Medical Centre
Nottingham NG7 2UH
UK
shirley.thomas@nottingham.ac.uk
Notes Exclusion criteria: unclear
HDRS: Hamilton Depression Rating Scale
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D A T A A N D A N A L Y S E S
Comparison 1. Pharmaceutical interventions versus placebo (antidepressants)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Depression: 1. Meeting study
criteria for depression
7 789 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.22, 0.98]
1.1 Clinician
interview/impression (number
improved)
1 206 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.27, 0.83]
1.2 DSM-III 1 26 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.22, 5.00]
1.3 HDRS 3 209 Odds Ratio (M-H, Random, 95% CI) 0.21 [0.03, 1.40]
1.4 MADRS 2 348 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.27, 2.62]
2 Depression: 2. Average change
in scores between baseline and
end of treatment
8 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 BDI (high score = more
depressed)
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.2 CGI (low score =
improvement / high score =
deterioration)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.3 HDRS (high score = more
depressed)
5 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.4 MADRS (high score =
more depressed)
3 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.5 Melancholia scale (high
score = more depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.6 Zung (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Depression: 3. Mean scores at
end of treatment
8 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 BDI (high score = more
depressed)
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.2 CGI (low score =
improvement / high score =
deterioration)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.3 HDRS (high score = more
depressed)
6 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.4 MADRS (high score =
more depressed)
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.5 Melancholia scale (high
score = more depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.6 Zung (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 Depression: 4. Less than 50%
reduction in scale scores
5 414 Odds Ratio (M-H, Random, 95% CI) 0.22 [0.09, 0.52]
4.1 HDRS 3 260 Odds Ratio (M-H, Random, 95% CI) 0.13 [0.06, 0.30]
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4.2 MADRS 2 154 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.27, 1.00]
5 Anxiety: 1. Meeting study
criteria for anxiety
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Clinician
interview/impression
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
6 Cognitive functioning: 1.
Average change in scores
between baseline and end of
treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 MMSE (low score =
cognitive impairment)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7 Cognitive functioning: 2. Mean
scores at end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 MMSE (low score =
cognitive impairment)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Activities of daily living: 1.
Average change in scores
between baseline and end of
treatment
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Barthel (high score = more
dependent)
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
9 Disability: 1. Average change in
scores between baseline and
end of treatment
3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Functional Independence
Measure (low score =
dependence)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
9.2 Motoricity Index
(low score = more motor
impairment)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
9.3 Scandinavian Stroke Scale
(low score = more neurological
deficit)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
9.4 Rankin Scale (high score =
more disability)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
10 Disability: 2. Mean scores at
end of treatment
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Functional Independence
Measure (low score =
dependence)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
10.2 Motoricity Index
(low score = more motor
impairment)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
10.3 Scandinavian Stroke
Scale (low score = more
neurological deficit)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
11 Neurological function: 1.
Average change in scores
between baseline and end of
treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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11.1 Chinese Stroke Scale
(high score = more impairment)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
12 Neurological function: 2. Mean
scores at end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Chinese Stroke Scale
(high score = more impairment)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
13 Adverse events: 1. Death 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 At end of treatment 6 537 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.15, 2.15]
14 Adverse events: 2. All 7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Central nervous system
events (e.g. confusion, sedation,
tremor)
5 488 Odds Ratio (M-H, Fixed, 95% CI) 1.96 [1.19, 3.24]
14.2 Gastrointestinal effects
(e.g. constipation, diarrhoea)
3 383 Odds Ratio (M-H, Fixed, 95% CI) 2.37 [1.38, 4.06]
14.3 Other events - not
listed above (e.g. dysuria, eye
discomfort)
6 544 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.97, 2.34]
14.4 Protocol violation (e.g.
refused treatment, withdrew
consent)
3 136 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.20, 3.66]
14.5 Psychiatric events (e.g.
anxiety, increased depression)
2 89 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.03, 3.47]
14.6 Recurrent stroke 2 105 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.15, 8.60]
14.7 Vascular events -
not stroke (e.g. dizziness,
palpitation)
7 583 Odds Ratio (M-H, Fixed, 95% CI) 1.60 [0.93, 2.73]
15 Adverse events: 3. Leaving the
study early (including death)
6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 all drop outs and
withdrawals
6 542 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.69, 1.59]
Comparison 2. Pharmaceutical interventions versus placebo (combination therapy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Depression: 1. Average change
in scores between baseline and
end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 HDRS (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Depression: 2. Mean scores at
end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 HDRS (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Neurological function: 1.
Average change in scores
between baseline and end of
treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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3.1 Chinese Stroke Scale (high
score = more impairment)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 Neurological function: 2. Mean
scores at end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Chinese Stroke Scale (high
score = more impairment)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Adverse events: 1. All 1 90 Odds Ratio (M-H, Fixed, 95% CI) 2.14 [0.23, 19.95]
5.1 Other events (GPT
elevation)
1 45 Odds Ratio (M-H, Fixed, 95% CI) 2.72 [0.12, 60.29]
5.2 Vascular events - not
stroke (e.g. ECG changes)
1 45 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.06, 41.03]
Comparison 3. Psychological interventions versus standard care and/or attention control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Depression: Meeting study
criteria for depression at end of
treatment
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 GHQ-28 (high score =
greater psychological distress)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Depression: 1. Average change
in scores between baseline and
end of treatment
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 BDI (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.2 WDI (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.3 HDRS (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Depression: 2. Mean scores at
end of treatment
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 BDI (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.2 WDI (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.3 HDRS (high score = more
depressed)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 Psychological distress: 1. Average
change in scores between
baseline and end of treatment
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 GHQ-28 (high score =
greater psychological distress)
2 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Psychological distress: 2. Mean
scores at end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 GHQ-28 (high score =
greater psychological distress)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
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6 Activities of daily living: 1.
Average change in scores from
baseline to end of treatment
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 EADL (high score = more
dependent)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
6.2 Barthel (high score = more
dependent)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7 Activities of daily living: 2. Mean
scores at end of treatment
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 EADL (high score = more
dependent)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7.2 Barthel (high score = more
dependent)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Adverse events: 1. Death 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 At end of treatment 3 421 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.11, 1.28]
9 Adverse events: 2. All 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Protocol violation (e.g.
refused treatment, withdrew
consent)
1 43 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.65]
9.2 Recurrent stroke 1 254 Odds Ratio (M-H, Fixed, 95% CI) 5.08 [0.24, 106.87]
9.3 Vascular events - not
stroke (e.g. transient ischaemic
attack)
1 254 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.22, 2.27]
10 Adverse events: 3. Leaving the
study early (including death)
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 All drop outs and
withdrawals
3 421 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.13, 1.17]
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Analysis 1.1. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 1
Depression: 1. Meeting study criteria for depression.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 1 Depression: 1. Meeting study criteria for depression
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinician interview/impression (number improved)
Ohtomo 1991 52/108 65/98 18.5 % 0.47 [ 0.27, 0.83 ]
Subtotal (95% CI) 108 98 18.5 % 0.47 [ 0.27, 0.83 ]
Total events: 52 (Treatment), 65 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0090)
2 DSM-III
Lipsey 1984 6/11 8/15 10.8 % 1.05 [ 0.22, 5.00 ]
Subtotal (95% CI) 11 15 10.8 % 1.05 [ 0.22, 5.00 ]
Total events: 6 (Treatment), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 HDRS
Andersen 1994 6/18 17/20 10.7 % 0.09 [ 0.02, 0.42 ]
Fruehwald 2003 8/26 6/24 13.1 % 1.33 [ 0.38, 4.63 ]
Yang 2002 33/64 53/57 14.0 % 0.08 [ 0.03, 0.25 ]
Subtotal (95% CI) 108 101 37.7 % 0.21 [ 0.03, 1.40 ]
Total events: 47 (Treatment), 76 (Control)
Heterogeneity: Tau2 = 2.29; Chi2 = 12.44, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 1.61 (P = 0.11)
4 MADRS
Murray 2002 12/62 8/61 15.2 % 1.59 [ 0.60, 4.21 ]
Ponzio 2001 82/111 97/114 17.7 % 0.50 [ 0.25, 0.97 ]
Subtotal (95% CI) 173 175 33.0 % 0.84 [ 0.27, 2.62 ]
Total events: 94 (Treatment), 105 (Control)
Heterogeneity: Tau2 = 0.50; Chi2 = 3.74, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.30 (P = 0.76)
Total (95% CI) 400 389 100.0 % 0.47 [ 0.22, 0.98 ]
Total events: 199 (Treatment), 254 (Control)
Heterogeneity: Tau2 = 0.68; Chi2 = 23.60, df = 6 (P = 0.00062); I2 =75%
Test for overall effect: Z = 2.02 (P = 0.043)
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Analysis 1.2. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 2
Depression: 2. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 2 Depression: 2. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BDI (high score = more depressed)
Fruehwald 2003 26 -6.1 (5.6) 24 -4.1 (6.48) -2.00 [ -5.37, 1.37 ]
Rampello 2005 16 -12.5 (11.62) 15 -1.47 (9.35) -11.03 [ -18.43, -3.63 ]
2 CGI (low score = improvement / high score = deterioration)
Fruehwald 2003 26 -2.7 (1.16) 24 -2.1 (1.36) -0.60 [ -1.30, 0.10 ]
3 HDRS (high score = more depressed)
Andersen 1994 33 -8 (4.22) 33 -4.8 (3.87) -3.20 [ -5.15, -1.25 ]
Fruehwald 2003 26 -23.3 (12) 24 -19.1 (15.1) -4.20 [ -11.80, 3.40 ]
Jiang 2001a 30 -20.13 (6.82) 15 -11.85 (7.5) -8.28 [ -12.79, -3.77 ]
Lipsey 1984 11 -11 (4.62) 15 -6.4 (7.94) -4.60 [ -9.46, 0.26 ]
Rampello 2005 16 -14.8 (4.9) 15 -1.27 (5.29) -13.53 [ -17.13, -9.93 ]
4 MADRS (high score = more depressed)
Murray 2002 62 -8.5 (8.9) 61 -7.6 (9.3) -0.90 [ -4.12, 2.32 ]
Ponzio 2001 112 -12 (9.52) 114 -9.9 (7.47) -2.10 [ -4.33, 0.13 ]
Wiart 2000 16 -16.7 (7.22) 15 -8.5 (8.36) -8.20 [ -13.71, -2.69 ]
5 Melancholia scale (high score = more depressed)
Andersen 1994 33 -7.2 (4.22) 33 -4.3 (3.67) -2.90 [ -4.81, -0.99 ]
6 Zung (high score = more depressed)
Lipsey 1984 11 -23 (7.28) 15 -12 (13.98) -11.00 [ -19.28, -2.72 ]
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Analysis 1.3. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 3
Depression: 3. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 3 Depression: 3. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BDI (high score = more depressed)
Fruehwald 2003 26 6.1 (5.6) 24 6.8 (7.4) -0.70 [ -4.36, 2.96 ]
Rampello 2005 16 8.06 (3.43) 15 18.4 (3.33) -10.34 [ -12.72, -7.96 ]
2 CGI (low score = improvement / high score = deterioration)
Fruehwald 2003 26 3.1 (1.3) 24 3.4 (1.7) -0.30 [ -1.14, 0.54 ]
3 HDRS (high score = more depressed)
Andersen 1994 33 11.4 (5.1) 33 14.1 (4.7) -2.70 [ -5.07, -0.33 ]
Fruehwald 2003 26 9.5 (7.9) 24 11.2 (12.4) -1.70 [ -7.52, 4.12 ]
Jiang 2001a 30 5.12 (3.11) 15 13.21 (5.56) -8.09 [ -11.12, -5.06 ]
Lai 2006a 40 12.5 (8.4) 40 21.5 (4.3) -9.00 [ -11.92, -6.08 ]
Lipsey 1984 11 2.8 (2.65) 15 10 (8.13) -7.20 [ -11.60, -2.80 ]
Rampello 2005 16 9.26 (2.15) 15 22.73 (2.4) -13.47 [ -15.08, -11.86 ]
4 MADRS (high score = more depressed)
Murray 2002 62 10.5 (9.6) 61 12 (8.5) -1.50 [ -4.70, 1.70 ]
Wiart 2000 16 11.8 (6.7) 15 18.7 (10) -6.90 [ -12.93, -0.87 ]
5 Melancholia scale (high score = more depressed)
Andersen 1994 33 10.5 (5.1) 33 12.9 (4.5) -2.40 [ -4.72, -0.08 ]
6 Zung (high score = more depressed)
Lipsey 1984 11 31 (9.95) 15 42 (15.49) -11.00 [ -20.80, -1.20 ]
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Analysis 1.4. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 4
Depression: 4. Less than 50% reduction in scale scores.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 4 Depression: 4. Less than 50% reduction in scale scores
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 HDRS
Andersen 1994 11/27 23/32 19.5 % 0.27 [ 0.09, 0.80 ]
Lai 2006a 18/40 34/40 19.8 % 0.14 [ 0.05, 0.42 ]
Yang 2002 10/64 42/57 21.6 % 0.07 [ 0.03, 0.16 ]
Subtotal (95% CI) 131 129 60.9 % 0.13 [ 0.06, 0.30 ]
Total events: 39 (Treatment), 99 (Control)
Heterogeneity: Tau2 = 0.26; Chi2 = 3.92, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 4.87 (P < 0.00001)
2 MADRS
Murray 2002 33/62 40/61 23.5 % 0.60 [ 0.29, 1.24 ]
Wiart 2000 6/16 10/15 15.6 % 0.30 [ 0.07, 1.31 ]
Subtotal (95% CI) 78 76 39.1 % 0.52 [ 0.27, 1.00 ]
Total events: 39 (Treatment), 50 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
Total (95% CI) 209 205 100.0 % 0.22 [ 0.09, 0.52 ]
Total events: 78 (Treatment), 149 (Control)
Heterogeneity: Tau2 = 0.71; Chi2 = 14.99, df = 4 (P = 0.005); I2 =73%
Test for overall effect: Z = 3.44 (P = 0.00057)
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Analysis 1.5. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 5
Anxiety: 1. Meeting study criteria for anxiety.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 5 Anxiety: 1. Meeting study criteria for anxiety
Study or subgroup Treatment Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Clinician interview/impression
Ohtomo 1991 46/93 57/85 0.48 [ 0.26, 0.88 ]
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Analysis 1.6. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 6
Cognitive functioning: 1. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 6 Cognitive functioning: 1. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 MMSE (low score = cognitive impairment)
Wiart 2000 16 1.3 (3.71) 15 2.1 (2.95) -0.80 [ -3.15, 1.55 ]
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Analysis 1.7. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 7
Cognitive functioning: 2. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 7 Cognitive functioning: 2. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 MMSE (low score = cognitive impairment)
Wiart 2000 16 24.8 (3.9) 15 26.2 (3) -1.40 [ -3.84, 1.04 ]
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Analysis 1.8. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 8
Activities of daily living: 1. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 8 Activities of daily living: 1. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Barthel (high score = more dependent)
Ponzio 2001 102 1.7 (0) 102 1.8 (0) 0.0 [ 0.0, 0.0 ]
Reding 1986 11 -28 (23.22) 6 -20 (17.5) -8.00 [ -27.61, 11.61 ]
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Analysis 1.9. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 9
Disability: 1. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 9 Disability: 1. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Functional Independence Measure (low score = dependence)
Wiart 2000 16 24.7 (20.37) 15 16.4 (23.2) 8.30 [ -7.11, 23.71 ]
2 Motoricity Index (low score = more motor impairment)
Wiart 2000 18 18.9 (23.81) 15 11.9 (26) 7.00 [ -10.15, 24.15 ]
3 Scandinavian Stroke Scale (low score = more neurological deficit)
Fruehwald 2003 26 13.55 (7.4) 24 15.4 (9.24) -1.85 [ -6.51, 2.81 ]
4 Rankin Scale (high score = more disability)
Ponzio 2001 102 -0.4 (0) 103 -0.4 (0) 0.0 [ 0.0, 0.0 ]
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Analysis 1.10. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 10
Disability: 2. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 10 Disability: 2. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Functional Independence Measure (low score = dependence)
Wiart 2000 16 87.4 (22.8) 15 88.7 (25.3) -1.30 [ -18.29, 15.69 ]
2 Motoricity Index (low score = more motor impairment)
Wiart 2000 16 48.5 (24.6) 15 55.3 (26.5) -6.80 [ -24.83, 11.23 ]
3 Scandinavian Stroke Scale (low score = more neurological deficit)
Fruehwald 2003 26 53.5 (4.8) 24 52.8 (5.4) 0.70 [ -2.14, 3.54 ]
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Analysis 1.11. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 11
Neurological function: 1. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 11 Neurological function: 1. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Chinese Stroke Scale (high score = more impairment)
Jiang 2001a 30 -14.81 (6.39) 15 -13.06 (6.78) -1.75 [ -5.87, 2.37 ]
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Analysis 1.12. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 12
Neurological function: 2. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 12 Neurological function: 2. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Chinese Stroke Scale (high score = more impairment)
Jiang 2001a 30 3.23 (2.37) 15 5.2 (3.27) -1.97 [ -3.83, -0.11 ]
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Analysis 1.13. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 13
Adverse events: 1. Death.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 13 Adverse events: 1. Death
Study or subgroup Treatment Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At end of treatment
Andersen 1994 1/33 1/33 1.00 [ 0.06, 16.69 ]
Fruehwald 2003 1/28 0/26 2.89 [ 0.11, 74.17 ]
Lipsey 1984 0/14 2/20 0.26 [ 0.01, 5.74 ]
Murray 2002 0/62 2/61 0.19 [ 0.01, 4.05 ]
Ponzio 2001 0/112 0/117 0.0 [ 0.0, 0.0 ]
Wiart 2000 0/16 0/15 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 265 272 0.57 [ 0.15, 2.15 ]
Total events: 2 (Treatment), 5 (Control)
Heterogeneity: Chi2 = 1.87, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
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Analysis 1.14. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 14
Adverse events: 2. All.
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 14 Adverse events: 2. All
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Central nervous system events (e.g. confusion, sedation, tremor)
Andersen 1994 2/33 0/33 2.1 % 5.32 [ 0.25, 115.13 ]
Lipsey 1984 4/17 0/22 1.5 % 15.00 [ 0.75, 300.87 ]
Murray 2002 33/62 28/61 59.2 % 1.34 [ 0.66, 2.72 ]
Ponzio 2001 17/112 8/117 29.8 % 2.44 [ 1.01, 5.90 ]
Wiart 2000 3/16 2/15 7.5 % 1.50 [ 0.21, 10.52 ]
Subtotal (95% CI) 240 248 100.0 % 1.96 [ 1.19, 3.24 ]
Total events: 59 (Treatment), 38 (Control)
Heterogeneity: Chi2 = 3.58, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0084)
2 Gastrointestinal effects (e.g. constipation, diarrhoea)
Murray 2002 44/62 27/61 45.3 % 3.08 [ 1.46, 6.49 ]
Ponzio 2001 17/112 8/117 38.1 % 2.44 [ 1.01, 5.90 ]
Wiart 2000 1/16 3/15 16.6 % 0.27 [ 0.02, 2.90 ]
Subtotal (95% CI) 190 193 100.0 % 2.37 [ 1.38, 4.06 ]
Total events: 62 (Treatment), 38 (Control)
Heterogeneity: Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 3.12 (P = 0.0018)
3 Other events - not listed above (e.g. dysuria, eye discomfort)
Andersen 1994 1/33 0/33 1.5 % 3.09 [ 0.12, 78.70 ]
Fruehwald 2003 0/26 1/24 4.7 % 0.30 [ 0.01, 7.61 ]
Jiang 2001a 2/30 0/15 1.9 % 2.72 [ 0.12, 60.29 ]
Murray 2002 37/62 26/61 32.5 % 1.99 [ 0.97, 4.08 ]
Ponzio 2001 29/112 26/117 58.0 % 1.22 [ 0.67, 2.24 ]
Wiart 2000 1/16 0/15 1.4 % 3.00 [ 0.11, 79.50 ]
Subtotal (95% CI) 279 265 100.0 % 1.51 [ 0.97, 2.34 ]
Total events: 70 (Treatment), 53 (Control)
Heterogeneity: Chi2 = 2.50, df = 5 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
0.01 0.1 1 10 100
Favours treatment Favours control
(Continued . . . )
72Interventions for treating depression after stroke (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
4 Protocol violation (e.g. refused treatment, withdrew consent)
Andersen 1994 1/33 0/33 12.1 % 3.09 [ 0.12, 78.70 ]
Lipsey 1984 0/17 3/22 75.9 % 0.16 [ 0.01, 3.30 ]
Wiart 2000 1/16 0/15 11.9 % 3.00 [ 0.11, 79.50 ]
Subtotal (95% CI) 66 70 100.0 % 0.85 [ 0.20, 3.66 ]
Total events: 2 (Treatment), 3 (Control)
Heterogeneity: Chi2 = 2.35, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 0.21 (P = 0.83)
5 Psychiatric events (e.g. anxiety, increased depression)
Fruehwald 2003 0/26 1/24 54.4 % 0.30 [ 0.01, 7.61 ]
Lipsey 1984 0/17 1/22 45.6 % 0.41 [ 0.02, 10.69 ]
Subtotal (95% CI) 43 46 100.0 % 0.35 [ 0.03, 3.47 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
6 Recurrent stroke
Andersen 1994 1/33 0/33 27.2 % 3.09 [ 0.12, 78.70 ]
Lipsey 1984 0/17 1/22 72.8 % 0.41 [ 0.02, 10.69 ]
Subtotal (95% CI) 50 55 100.0 % 1.14 [ 0.15, 8.60 ]
Total events: 1 (Treatment), 1 (Control)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
7 Vascular events - not stroke (e.g. dizziness, palpitation)
Andersen 1994 1/33 1/33 4.5 % 1.00 [ 0.06, 16.69 ]
Fruehwald 2003 1/26 0/24 2.3 % 2.88 [ 0.11, 74.21 ]
Jiang 2001a 7/30 0/15 2.3 % 9.89 [ 0.53, 185.97 ]
Lipsey 1984 2/17 1/22 3.6 % 2.80 [ 0.23, 33.78 ]
Murray 2002 22/62 18/61 54.9 % 1.31 [ 0.62, 2.80 ]
Ponzio 2001 9/112 6/117 25.3 % 1.62 [ 0.56, 4.70 ]
Wiart 2000 0/16 1/15 7.0 % 0.29 [ 0.01, 7.76 ]
Subtotal (95% CI) 296 287 100.0 % 1.60 [ 0.93, 2.73 ]
Total events: 42 (Treatment), 27 (Control)
Heterogeneity: Chi2 = 3.20, df = 6 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
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Analysis 1.15. Comparison 1 Pharmaceutical interventions versus placebo (antidepressants), Outcome 15
Adverse events: 3. Leaving the study early (including death).
Review: Interventions for treating depression after stroke
Comparison: 1 Pharmaceutical interventions versus placebo (antidepressants)
Outcome: 15 Adverse events: 3. Leaving the study early (including death)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 all drop outs and withdrawals
Andersen 1994 7/33 2/33 3.7 % 4.17 [ 0.80, 21.85 ]
Fruehwald 2003 2/28 2/26 4.5 % 0.92 [ 0.12, 7.08 ]
Lipsey 1984 6/17 7/22 9.3 % 1.17 [ 0.31, 4.46 ]
Murray 2002 24/62 30/61 43.6 % 0.65 [ 0.32, 1.34 ]
Ponzio 2001 20/112 20/117 37.8 % 1.05 [ 0.53, 2.09 ]
Wiart 2000 2/16 0/15 1.0 % 5.34 [ 0.24, 121.00 ]
Subtotal (95% CI) 268 274 100.0 % 1.04 [ 0.69, 1.59 ]
Total events: 61 (Treatment), 61 (Control)
Heterogeneity: Chi2 = 5.44, df = 5 (P = 0.36); I2 =8%
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 2.1. Comparison 2 Pharmaceutical interventions versus placebo (combination therapy), Outcome
1 Depression: 1. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 2 Pharmaceutical interventions versus placebo (combination therapy)
Outcome: 1 Depression: 1. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HDRS (high score = more depressed)
Jiang 2001b 30 -19.94 (6.66) 15 -11.85 (7.5) -8.09 [ -12.57, -3.61 ]
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Analysis 2.2. Comparison 2 Pharmaceutical interventions versus placebo (combination therapy), Outcome
2 Depression: 2. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 2 Pharmaceutical interventions versus placebo (combination therapy)
Outcome: 2 Depression: 2. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HDRS (high score = more depressed)
Jiang 2001b 30 4.9 (2.96) 15 13.21 (5.56) -8.31 [ -11.32, -5.30 ]
-10 -5 0 5 10
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Analysis 2.3. Comparison 2 Pharmaceutical interventions versus placebo (combination therapy), Outcome
3 Neurological function: 1. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 2 Pharmaceutical interventions versus placebo (combination therapy)
Outcome: 3 Neurological function: 1. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Chinese Stroke Scale (high score = more impairment)
Jiang 2001b 30 -14.85 (6.25) 15 -13.06 (6.78) -1.79 [ -5.89, 2.31 ]
-10 -5 0 5 10
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Analysis 2.4. Comparison 2 Pharmaceutical interventions versus placebo (combination therapy), Outcome
4 Neurological function: 2. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 2 Pharmaceutical interventions versus placebo (combination therapy)
Outcome: 4 Neurological function: 2. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Chinese Stroke Scale (high score = more impairment)
Jiang 2001b 30 3.01 (2.12) 15 5.2 (3.27) -2.19 [ -4.01, -0.37 ]
-10 -5 0 5 10
Favours treatment Favours control
Analysis 2.5. Comparison 2 Pharmaceutical interventions versus placebo (combination therapy), Outcome
5 Adverse events: 1. All.
Review: Interventions for treating depression after stroke
Comparison: 2 Pharmaceutical interventions versus placebo (combination therapy)
Outcome: 5 Adverse events: 1. All
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Other events (GPT elevation)
Jiang 2001b 2/30 0/15 49.1 % 2.72 [ 0.12, 60.29 ]
Subtotal (95% CI) 30 15 49.1 % 2.72 [ 0.12, 60.29 ]
Total events: 2 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 Vascular events - not stroke (e.g. ECG changes)
Jiang 2001b 1/30 0/15 50.9 % 1.58 [ 0.06, 41.03 ]
Subtotal (95% CI) 30 15 50.9 % 1.58 [ 0.06, 41.03 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
Total (95% CI) 60 30 100.0 % 2.14 [ 0.23, 19.95 ]
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(. . . Continued)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 3 (Treatment), 0 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 3.1. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 1 Depression: Meeting study criteria for depression at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 1 Depression: Meeting study criteria for depression at end of treatment
Study or subgroup Treatment Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 GHQ-28 (high score = greater psychological distress)
Watkins 2007 85/127 95/127 0.68 [ 0.40, 1.18 ]
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Analysis 3.2. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 2 Depression: 1. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 2 Depression: 1. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BDI (high score = more depressed)
Lincoln 2003 38 -3 (8.99) 80 -3 (8.12) 0.0 [ -3.37, 3.37 ]
2 WDI (high score = more depressed)
Lincoln 2003 38 -3.77 (6.84) 80 -3 (6.36) -0.77 [ -3.35, 1.81 ]
3 HDRS (high score = more depressed)
Zhao 2004 35 -13.11 (15.79) 35 -7.07 (15.79) -6.04 [ -13.44, 1.36 ]
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Analysis 3.3. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 3 Depression: 2. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 3 Depression: 2. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BDI (high score = more depressed)
Lincoln 2003 38 15.21 (10.1) 80 15 (8.41) 0.21 [ -3.49, 3.91 ]
2 WDI (high score = more depressed)
Lincoln 2003 38 18.97 (8.34) 80 19 (7.14) -0.03 [ -3.11, 3.05 ]
3 HDRS (high score = more depressed)
Zhao 2004 35 14.35 (3.12) 35 21.07 (2.5) -6.72 [ -8.04, -5.40 ]
-10 -5 0 5 10
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Analysis 3.4. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 4 Psychological distress: 1. Average change in scores between baseline and end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 4 Psychological distress: 1. Average change in scores between baseline and end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 GHQ-28 (high score = greater psychological distress)
Lincoln 2003 38 -6.18 (15.31) 81 -7 (15.3) 0.82 [ -5.08, 6.72 ]
Watkins 2007 127 -1.3 (7.1) 127 -1 (7.2) -0.30 [ -2.06, 1.46 ]
-10 -5 0 5 10
Favours treatment Favours control
Analysis 3.5. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 5 Psychological distress: 2. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 5 Psychological distress: 2. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 GHQ-28 (high score = greater psychological distress)
Lincoln 2003 38 28.79 (16.71) 81 27 (15.17) 1.79 [ -4.47, 8.05 ]
-10 -5 0 5 10
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Analysis 3.6. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 6 Activities of daily living: 1. Average change in scores from baseline to end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 6 Activities of daily living: 1. Average change in scores from baseline to end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 EADL (high score = more dependent)
Lincoln 2003 38 -5.4 (13.31) 81 -4 (14.69) -1.40 [ -6.71, 3.91 ]
2 Barthel (high score = more dependent)
Watkins 2007 124 -1.4 (3.9) 119 -1.4 (4.4) 0.0 [ -1.05, 1.05 ]
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Analysis 3.7. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 7 Activities of daily living: 2. Mean scores at end of treatment.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 7 Activities of daily living: 2. Mean scores at end of treatment
Study or subgroup Treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 EADL (high score = more dependent)
Lincoln 2003 38 30.29 (12.78) 81 32 (15.75) -1.71 [ -7.03, 3.61 ]
2 Barthel (high score = more dependent)
Watkins 2007 124 16.2 (4.3) 119 16.8 (3.8) -0.60 [ -1.62, 0.42 ]
-10 -5 0 5 10
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Analysis 3.8. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 8 Adverse events: 1. Death.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 8 Adverse events: 1. Death
Study or subgroup Treatment Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At end of treatment
Lincoln 2003 0/39 2/84 0.42 [ 0.02, 8.91 ]
Towle 1989 0/21 0/23 0.0 [ 0.0, 0.0 ]
Watkins 2007 3/127 8/127 0.36 [ 0.09, 1.39 ]
Subtotal (95% CI) 187 234 0.37 [ 0.11, 1.28 ]
Total events: 3 (Treatment), 10 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
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Analysis 3.9. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 9 Adverse events: 2. All.
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 9 Adverse events: 2. All
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Protocol violation (e.g. refused treatment, withdrew consent)
Towle 1989 0/21 1/22 100.0 % 0.33 [ 0.01, 8.65 ]
Subtotal (95% CI) 21 22 100.0 % 0.33 [ 0.01, 8.65 ]
Total events: 0 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Recurrent stroke
Watkins 2007 2/127 0/127 100.0 % 5.08 [ 0.24, 106.87 ]
Subtotal (95% CI) 127 127 100.0 % 5.08 [ 0.24, 106.87 ]
Total events: 2 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.30)
3 Vascular events - not stroke (e.g. transient ischaemic attack)
Watkins 2007 5/127 7/127 100.0 % 0.70 [ 0.22, 2.27 ]
Subtotal (95% CI) 127 127 100.0 % 0.70 [ 0.22, 2.27 ]
Total events: 5 (Treatment), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
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Analysis 3.10. Comparison 3 Psychological interventions versus standard care and/or attention control,
Outcome 10 Adverse events: 3. Leaving the study early (including death).
Review: Interventions for treating depression after stroke
Comparison: 3 Psychological interventions versus standard care and/or attention control
Outcome: 10 Adverse events: 3. Leaving the study early (including death)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All drop outs and withdrawals
Lincoln 2003 1/39 4/84 21.2 % 0.53 [ 0.06, 4.87 ]
Towle 1989 0/21 1/23 12.0 % 0.35 [ 0.01, 9.04 ]
Watkins 2007 3/127 8/127 66.8 % 0.36 [ 0.09, 1.39 ]
Subtotal (95% CI) 187 234 100.0 % 0.39 [ 0.13, 1.17 ]
Total events: 4 (Treatment), 13 (Control)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.094)
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A D D I T I O N A L T A B L E S
Table 1. Characteristics of ’drop-out’ studies
Study ID Methods Participants Interventions Outcomes Notes Allocation
Choi-Kwon
2006
Parallel design
Method of ran-
domisation:
computer-
generated list of
treatment num-
bers
Method of con-
cealment:
unclear
Blinding:
double blind
Particiapnts: yes
Investigators:
yes
Relatives: yes
Outcome asses-
sors: no
Location: Seoul
Setting:
outpatients
Treat-
ment: 76 (75%
male, mean age
58 years, SD 9)
Con-
trol: 76 (79%
male, mean age
58 years, SD 9)
Stroke criteria:
ischaemic stroke;
diagnosis via CT
and MRI scans;
interview per-
formed on aver-
age of 14months
Treatment: flu-
oxetine 20 mg
daily
Control:
matched
placebo
Duration: treat-
ment continued
for 3 months
Depression:
change in scores
from baseline to
end of treatment
and endof follow
up on BDI
Additional: leav-
ing the
study early, ad-
verse events
Unable to use:
outcome data
not presented in
a format suitable
for this review
Exclusion crite-
ria:
did not undergo
imaging (CT/
MRI) studies,
SAH, had TIA
without progres-
sion to stroke,
severe communi-
cation problems
(aphasia, demen-
tia, or dysarthria,
scored < 23 on
MMSE, history
of depression
or psychiatric ill-
A
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Table 1. Characteristics of ’drop-out’ studies (Continued)
Analysis:
ITT:
27 withdrew be-
fore com-
pleting 3-month
treatment proto-
col, with-
drew due to pro-
tocol violation (4
treatment,
6 control), with-
drew due to AE
(10 treatment, 2
control),
withdrawn
due to readmis-
sion into hos-
pital because of
other diseases (1
treatment,
2 control), with-
drew due to be-
lieving treatment
was not effective
(2 control)
after stroke
De-
pression criteria:
psychiatric inter-
view, BDI score
> 13
Other en-
try criteria: none
stated
Comparabil-
ity of treatment
groups: non-sig-
nificant trend to-
wards right-
sided lesion
strokes in con-
trol group and
left-sided lesion
strokes in treat-
ment group
ness before onset
of stroke, already
treated with psy-
chiatric regi-
mens, lived alone
Downes 1995 Parallel design
Method of ran-
domisation: ran-
dom number se-
quence stratified
by Rankin score
Method of con-
cealment: ran-
domised by one
of the authors
Blinding: single
blind
Participants: no
Investigators: no
Outcome asses-
sors: yes
Analy-
sis: per protocol:
105 participants
randomised, 87
available
at 6 months, 18
lost to follow up
Location: UK
Setting:
outpatient
Treatment 1: 22
(50% male, age
not reported)
Treatment 2: 22
(55% male, age
not reported)
Control: 18
(44% male, age
not reported)
Stroke criteria:
unclear; no cri-
teria defined in
study for time
from stroke to
randomisation
Other entry cri-
teria:
lived at home,
had an informal
carer, stroke in-
Treatment 1: in-
formation
plus counselling.
Egan’s
problem solving
approach, indi-
vidual is helped
to explore con-
cerns, clar-
ify problems, set
goal and take ap-
propriate action.
Protocol dis-
cussed first and
formulated into
a coun-
sellor/client con-
tract. Informa-
tion pack con-
taining informa-
tion on physical,
cognitive,
Depression:
change in scores
from baseline to
end of treatment
on HADS
Ad-
ditional: HADS
anxiety score
Unable to use: all
data
presented com-
bines both de-
pressed and non-
depressed partic-
ipants at baseline
Exclusion crite-
ria: not living at
home, not hav-
ing an informal
carer, having no
increase in dis-
ability or change
in lifestyle/
dependency
B
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Table 1. Characteristics of ’drop-out’ studies (Continued)
(no reason given)
, 25 not assessed
(no reason given)
, 43 excluded
from analysis
crease mRS,
post-stroke mRS
score of 2 to 5
Comparabil-
ity of treatment
groups: balanced
behavioural and
emotional effects
of stroke, carer
well-being, and
local services.
Treatment 2: in-
formation only:
informa-
tion pack con-
taining informa-
tion on physical,
cognitive,
behavioural and
emotional effects
of stroke, carer
well-being, and
local services.
Control:
standard care, no
visit(s) or infor-
mationpack pro-
vided
Duration: infor-
mation ses-
sion consisted of
1 visit and pro-
vision of the in-
formation pack
Counselling
consisted of up
to 8 counselling
sessions over 4 to
6 months
Delivered by:
nurse counsellor
Graffagnino
2003
Parallel design
Method of ran-
domisation: un-
clear
Method of con-
cealment:
unclear
Blinding:
unclear
Analysis: unclear
Location:
unclear
Setting: unclear
Treatment: un-
clear
Control: unclear
Stroke criteria:
unclear
Depression cri-
teria: unclear
Other entry cri-
teria: unclear
Comparabil-
Treatment: ser-
traline
Control:
matched
placebo
Duration:
unclear
Depression: un-
clear
Additional: un-
clear
Unable to
use: no data pre-
sented
Exclusion crite-
ria: unclear
B
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Table 1. Characteristics of ’drop-out’ studies (Continued)
ity of treatment
groups: unclear
Isenberg 2000 Parallel design
Method of ran-
domisation: un-
clear
Method of con-
cealment:
unclear
Blinding: double
blind
Location:
unclear
Setting: unclear
Treatment:
nefiracetam
Control: unclear
Stroke criteria:
unclear
Depression cri-
teria: unclear
Other entry cri-
teria: par-
ticipants must be
at least 3 months
poststroke
Comparabil-
ity of treatment
groups: unclear
Treatment:
nefiracetam
Control:
matched
placebo
Duration:
unclear
Depression: un-
clear
Additional: un-
clear
Unable to use:
no results avail-
able
Exclusion crite-
ria: unclear
B
Mauri 1988 Parallel design
Method of ran-
domisation: un-
clear
Method of con-
cealment:
unclear
Blinding:
unclear
Analysis: unclear
Location: Spain
Setting: unclear
Treatment: mi-
anserin, 6 weeks,
dose unclear
Control:
placebo
Stroke cri-
teria: ischaemic
stroke, diagnosis
unclear; stroke 6
months prior to
randomisation
Depression cri-
teria: GDS (15
item) score > 4
Other en-
try criteria: none
stated
Comparabil-
ity of treatment
groups: unclear
Treatment: mi-
anserin
Control:
placebo
Duration: treat-
ment continued
for 6 weeks
Depression: un-
clear
Additional: un-
clear
Unable to use:
results not avail-
able in format
suitable for this
review
Exclusion crite-
ria: unclear
B
Meara 1998 Parallel design
Method of ran-
domisation: un-
clear
Location: Wales,
UK
Setting:
inpatient
Treatment: ser-
traline, 50 mg,
daily
Dose esca-
Depression:
change in scores
from baseline to
end of treatment
Exclusion crite-
ria: moderate to
severe dementia,
severe aphasia,
B
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Table 1. Characteristics of ’drop-out’ studies (Continued)
Method of con-
cealment:
unclear
Blinding: double
blind reported,
those blinded
not stated
Analysis: unclear
Treatment: un-
clear
Control: unclear
Stroke cri-
teria: ischaemic
stroke, diagnosis
unclear; stroke >
11 weeks prior to
randomisation
Depression cri-
teria: GDS (15
item) score > 4
Other en-
try criteria: none
stated
Comparabil-
ity of treatment
groups: balanced
lation to 100 mg
for non-respon-
ders at 2 weeks
Control:
matched
placebo
Duration: treat-
ment continued
for 6 weeks
on GDS
Unable to use:
GDS,
BI, MMSE, FAI,
FAST,
leaving the study
early, death (data
not presented)
Ad-
verse events (data
not presented by
treatment group,
9 patients devel-
oped side effects,
generally mild
and transient)
commu-
nication difficul-
ties, poorly con-
trolled epilepsy
Ohtomo 1985 Parallel design
Method of ran-
domisation: un-
clear
Method of con-
cealment:
unclear
Blinding: double
bind reported,
those blinded
not stated
Anal-
ysis: per proto-
col: protocol vio-
lation (1 control)
, excluded from
analysis
Location: Japan
Setting: unclear
Treatment: 141
(54% male, age
details unclear)
Control: 147
(61% male, age
details unclear)
Stroke
criteria: all sub-
types; diagnosis
via clinical signs
and CT (% not
reported); time
from stroke to
randomisation
not reported
Other en-
try criteria: > 40
years of age, high
blood pressure (>
160/90 mmHg)
and hypertensive
changes on fun-
doscopy
changes, stable
Neuroleptic, mi-
nor tranquilliser,
antidepressant,
Treatment:
tiapride,
75 mg daily for 1
week, dose esca-
lation to 150 to
225 mg daily for
5 weeks accord-
ing to clinical re-
sponse
Control:
matched
placebo
Duration: treat-
ment continued
for 6 weeks
Depression: un-
clear
Unable to
use: no data pre-
sented by
’not depressed at
baseline’
Exclusion crite-
ria: severe apha-
sia, severe de-
mentia, drug de-
pendence, inade-
quate conditions
for the study
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Table 1. Characteristics of ’drop-out’ studies (Continued)
brain metabolic
activators, cere-
bro-vasodilators
washed out for 3
to 7 days prior to
randomisation
Comparabil-
ity of treatment
groups: balanced
Xie 2003 Parallel design
Method of ran-
domisation: un-
clear, ’paired’
Method of con-
cealment:
unclear
Blinding:
unclear
Analysis: unclear
Location: China
Setting: unclear
Treatment:
41 (% male un-
clear, mean age
64 years SD 7)
Control:
41 (% male un-
clear, mean age
62 years SD 5)
Stroke criteria:
infarction and
cerebral haemor-
rhage; time from
stroke to ran-
domisation not
reported
Other entry cri-
te-
ria: hemiplegia,
admitted during
January 1988 to
July 2002
Comparabil-
ity of treatment
groups: balanced
Treatment: psy-
chological inter-
vention: feeling
support therapy,
recognition ther-
apy, collec-
tive therapy, so-
cial support and
skills train-
ing, plus rou-
tine drug treat-
ment and reha-
bilitation train-
ing
Control: routine
drug treat-
ment and reha-
bilitation train-
ing
Duration:
unclear
Delivered by:
unclear
Depression: end-
point but
methodof assess-
ment unclear
Additional:
panic, anxiety,
stubborn, hostil-
ity
Unable to use:
Method of as-
sessment
not clear, SCL-
90 stated
but outcomes re-
ported are differ-
ent
Exclusion crite-
ria: unclear
B
Zhou 2004 Parallel design
Method of ran-
domisation:
unclear, ’equally
randomised’
Method of con-
cealment:
unclear
Blinding:
unclear
Analysis: unclear
Location: China
Setting: unclear
Treat-
ment: 50 (56%
male, mean age
63.8 years)
Control:
50 (60% male,
mean age 65.4
years)
Stroke crite-
ria: unclear; time
Treatment: reha-
bilitation
therapy plus psy-
chological nurs-
ing strategy in-
volv-
ing many people
including carers
and a buddy sys-
tem
Control: rehabil-
itation therapy
Depression:
multimodal ap-
proach to diag-
nosis, Beck De-
pression Inven-
tory, HDRS
Ad-
ditional: physical
function
Exclusion crite-
ria: unclear
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Table 1. Characteristics of ’drop-out’ studies (Continued)
from stroke to
randomisation
not reported
Other entry cri-
teria: unclear
Comparabil-
ity of treatment
groups: unclear
Duration: 6
weeks
Delivered by:
unclear
AE: adverse event(s)
BDI: Beck Depression Inventory
CT: computed tomography
BI: Barthel Index
FAI: Frenchay Activities Index
FAST: Frenchay Aphasia Screening Test
GDS: Geriatric Depression Scale
HADS: Hospital Anxiety and Depression Scale
HDRS: Hamilton Depression Rating Scale
ITT: intention to treat
MMSE: Mini-Mental State Examination
MRI: magnetic resonance imaging
mRS: modified Rankin Scale
SAH: subarachnoid haemorrhage
TIA: transient ischaemic attack
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
We used the following search strategy using a combination of controlled vocabulary and free text terms for MEDLINE and CINAHL
(Ovid), and modified it to suit the other databases.
1 exp cerebrovascular disorders/
2 (stroke$ or poststroke$ or cva$).tw.
3 (cerebrovascular$ or cerebral vascular).tw.
4 (cerebral or cerebellar or brain$ or vertebrobasilar).tw.
5 (infarct$ or isch?emi$ or thrombo$ or emboli$ or apoplexy).tw.
6 (cerebral or intracerebral or intracranial or brain$).tw.
7 (haemorrhage or hemorrhage or bleed$).tw.
8 4 and 5
9 6 and 7
10 1 or 2 or 3 or 8 or 9
11 Depression/
12 Depression, involutional/ or Depressive disorder/ or Dysthymic disorder/
13 (depress$ or dysthymi$).tw.
14 11 or 12 or 13
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15 10 and 14
16 randomized controlled trial.pt.
17 randomized controlled trials/
18 controlled clinical trial.pt.
19 controlled clinical trials/
20 random allocation/
21 double-blind method/
22 single-blind method/
23 clinical trial.pt.
24 exp clinical trials/
25 (clin$ adj25 trial$).tw.
26 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw.
27 placebos/
28 placebo$.tw.
29 random$.tw.
30 research design/
31 clinical trial phase ii.pt.
32 clinical trial phase iii.pt.
33 clinical trial phase iv.pt.
34 meta analysis.pt.
35 multicenter study.pt.
36 intervention studies/
37 cross-over studies/
38 meta-analysis/
39 control$.tw.
40 alternate treatment.tw.
41 “comparative study”/
42 exp evaluation studies/
43 Follow-up studies/
44 Prospective studies/
45 prospective.tw.
46 (versus or sham or intervention group or comparative stud$).tw.
47 or/16-46
48 15 and 47
49 limit 48 to human
WH A T ’ S N E W
Last assessed as up-to-date: 25 May 2008.
Date Event Description
28 March 2008 Amended Converted to new review format.
14 March 2008 New search has been performed The searches for the review were completed to February
2008.
Seven new trials have been added: six pharmacological in-
terventions making a total of 13, and two psychological
interventions making a total of four comparisons. There
are now 16 included trials with 1655 participants
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(Continued)
Eight trials require more information before they can be
assessed for inclusion in the review (down from 14 in the
previous version). Nine trials appear to meet the review
inclusion criteria but information is not available in a for-
mat suitable for pooling. Three studies are ongoing (up
from 0 in the previous version)
14 March 2008 New citation required and conclusions have changed This version of the review found a small but significant
effect of pharmacotherapy (not psychotherapy) on treating
depression and reducing depressive symptoms in stroke
patients
There has also been a change of authorship.
H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 3, 2004
C O N T R I B U T I O N S O F A U T H O R S
The first three review authors had equal input into the development, writing, and editing of the protocol and undertook the work
necessary to complete the review. JX assisted with obtaining and translating and extracting data from Chinese studies for the updated
review. The update was completed by MH.
D E C L A R A T I O N S O F I N T E R E S T
None known
S O U R C E S O F S U P P O R T
Internal sources
• The George Institute for International Health, Australia.
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External sources
• Stroke Society of Australasia, Overseas Study Scholarship, Australia.
• The Academic Unit of Psychiatry, The University of Leeds, UK.
• The Department of Clinical Neurosciences, The University of Edinburgh, UK.
• The Clinical Trials Research Unit, The University of Auckland, New Zealand.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents [adverse effects; therapeutic use]; Anxiety [chemically induced]; Depression [∗therapy]; Psychotherapy; Ran-
domized Controlled Trials as Topic; Stroke [∗psychology]
MeSH check words
Humans
92Interventions for treating depression after stroke (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
